Dscam inhibitory nucleic acids and methods of use thereof
Patent Information
- Application Number
- PCT/US2024/025688
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-20
- Filing Date
- 2024-04-22
- Publication Date
- 2024-12-05
AI Technical Summary
Current cell transplantation methods for treating glaucoma and other neurodegenerative disorders face challenges in improving donor retinal ganglion cell integration due to limited capacity for regeneration in the mammalian retina, with Down Syndrome Cell Adhesion Molecule (DSCAM) hindering the integration process.
Inhibitory nucleic acids, such as short hairpin RNA (shRNA) or anti-sense oligonucleotides, are used to block DSCAM expression in donor cells, enhancing their integration into the ganglion cell layer by modifying the host microenvironment with neurotrophic factors like BDNF and GDNF.
Blocking DSCAM expression improves donor neuron integration, leading to enhanced grafting outcomes and improved vision restoration in glaucoma treatment by facilitating better migration and integration of donor cells into the retina.
Smart Images

Figure US2024025688_05122024_PF_FP_ABST
Abstract
Description
[0001] DSCAM INHIBITORY NUCLEIC ACIDS AND METHODS OF USE THEREOF
[0002] CROSS-REFERENCE TO RELATED APPLICATION
[0003] This application claims the benefit of U.S. Patent Application Serial No. 63 / 460,855, filed on April 20, 2023. The disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application.
[0004] STATEMENT AS TO FEDERALLY FUNDED RESEARCH
[0005] This invention was made with government support under 1 F32EY033211 -01 A1 awarded by the NIH-NEI National Eye Institute. The government has certain rights in the invention.
[0006] BACKGROUND
[0007] This application relates to improving donor cell integration following transplantation.
[0008] Approximately 3.5% of the world’s population over 40 has glaucoma, the most common optic neuropathy. By 2040, the global prevalence of glaucoma will exceed 110 million people as the population ages, making it a high-priority target for therapy development. Although several neuroprotective approaches focused on preserving existing cells and their axons are being explored, this strategy alone will not restore vision already lost due to cell death. The mammalian retina has a limited capacity to regenerate; thus, retinal neuron death leads to irreversible vision loss. Retinal ganglion cell (RGC) replacement is needed to recover sight loss to glaucoma.
[0009] Cell transplantation has been proposed to replace retinal ganglion cells (RGCs) lost in glaucoma. Donor RGC survival and integration can be improved by altering the host microenvironment with neurotropic factors and chemokines. However, most donor RGCs still fail to integrate into the ganglion cell layer (GCL).
[0010] Accordingly, there exists a need for improved cell transplantation methods and compositions in treating glaucoma and other neurodegenerative disorders.
[0011] SUMMARY OF THE INVENTION
[0012] In an aspect, the invention features a mammalian cell including an inhibitory nucleic acid molecule capable of inhibiting expression of Down Syndrome Cell Adhesion Molecule (DSCAM).
[0013] In some embodiments, the inhibitory nucleic acid molecule is a short hairpin RNA (shRNA), an anti-sense oligonucleotide (ASO), a small interfering RNA (siRNA), a double-stranded RNA (dsRNA), or a microRNA (miRNA). In some embodiments, the inhibitory nucleic acid molecule is a shRNA.
[0014] In some embodiments, the shRNA includes a sequence complementary to at least 10 contiguous nucleotides (e.g., at least 11 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21 , or at least 22 contiguous nucleotides) of a nucleic acid sequence encoding DSCAM. In some embodiments, the shRNA includes a sequence of ACCAATGGCACTCTCCAAATTTTAGTGAAGCCACAGATGTAAAATTTGGAGAGTGCCATTGGG (SEQ ID NO: 9). In some embodiments, the shRNA includes a sequence of CCCTGTACCAGGCTCGAATAAATAGTGAAGCCACAGATGTATTTATTCGAGCCTGGTACAGGA (SEQ ID NO: 10).
[0015] In some embodiments, expression of the inhibitory nucleic acid is driven by an inducible promoter. In some embodiments, the inducible promoter is a doxycycline-inducible promoter.
[0016] In some embodiments, the mammalian cell is a human cell. In some embodiments, the human cell is a retinal ganglion cell (RGC). In some embodiments, the human cell is a neuron (for example, a dopaminergic neuron, neuronal precursor, or motor neuron).
[0017] In another aspect, the invention features a vector comprising an inhibitory nucleic acid molecule capable of inhibiting expression of DSCAM. In some embodiments, the vector is a lentivirus. In some embodiments, the vector includes the sequence of SEQ ID NO: 11 .
[0018] In another aspect, the invention features a composition including a mammalian cell described herein.
[0019] In some embodiments, the composition further includes doxycycline.
[0020] In another aspect, the invention features a composition including a mammalian cell and a DSCAM inhibitor.
[0021] In some embodiments, the DSCAM inhibitor is an anti-DSCAM antibody or antigen-binding fragment thereof.
[0022] In some embodiments, the mammalian cell is a human cell. In some embodiments, the human cell is a RGC. In some embodiments, the human cell is a neuron (for example, a dopaminergic neuron, neuronal precursor, or motor neuron).
[0023] In some embodiments, the composition further includes brain-derived neurotrophic factor (BDNF). In some embodiments, the composition further includes glial cell-derived neurotrophic factor (GDNF). In some embodiments, the composition further includes BDNF and GDNF.
[0024] In some embodiments, the composition further includes a neurotropic factor or chemokine. In some embodiments, the neurotropic factor or chemokine is SDF-1 .
[0025] In another aspect, the invention features a method of treating a subject, the method including administering to the subject a composition described herein.
[0026] In some embodiments, the method further includes administering to the subject a neurotropic factor or chemokine. In some embodiments, the neurotropic factor or chemokine is SDF-1 .
[0027] In some embodiments, the neurotropic factor or chemokine is administered to the subject (a) after administration of the composition; (b) before administration of the composition; or (c) simultaneously with administration of the composition.
[0028] In another aspect, the invention features a method of treating a subject, the method including administering to the subject a composition described herein.
[0029] In some embodiments, the subject has degeneration of the optic nerve. In some embodiments, the subject has glaucoma.
[0030] In some embodiments, the composition is administered intravitreally or subretinally.
[0031] In some embodiments, the neurotropic factor or chemokine is administered to the subject intravitreally or subretinally.
[0032] In some embodiments, subject is a human.
[0033] Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims.
[0034] One advantage is that blocking or silencing DSCAM in donor neurons and host ecosystem using gene or protein-based tools can improve donor neuron integration for cell replacement therapies.
[0035] BRIEF DESCRIPTION OF THE DRAWINGS
[0036] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application with color drawings will be provided by the Office upon request and payment of the necessary fee.
[0037] FIGURES 1A-1B show lentiviral production of DSCAM knockout retinal ganglion cells.
[0038] FIGURE 2 shows DSCAM knockout (KO) improves donor retinal ganglion cell integration into the ganglion cell layer in mice.
[0039] FIGURE 3 shows combining DSCAM KO (genetic) with chemokines improves donor RGC integration.
[0040] FIGURE 4 shows delivering anti-DSCAM antibodies has a similar effect as DSCAM knockout on improving donor RGC transplantation outcome and results in enhanced donor RGC grafting. Two antibodies were tested (R&D Systems AF3666 and Novus NB100-41390).
[0041] FIGURE 5 shows anti-DSCAM antibodies enable donor RGCs to integrate into the ganglion cell layer following intravitreal delivery.
[0042] Definitions
[0043] As used herein, the term “about” refers to a value that is within 10% above or below the value being described.
[0044] As used herein, the “length” of a nucleic acid refers to the linear size of the nucleic acid as assessed by measuring the quantity of nucleotides from the 5’ to the 3’ end of the nucleic acid. Exemplary molecular biology techniques that may be used to determine the length of a nucleic acid of interest are known in the art.
[0045] “Percent (%) sequence identity” with respect to a reference polynucleotide or polypeptide sequence is defined as the percentage of nucleic acids or amino acids in a candidate sequence that are identical to the nucleic acids or amino acids in the reference polynucleotide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid or amino acid sequence identity can be achieved in various ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For example, percent sequence identity values may be generated using the sequence comparison computer program BLAST. As an illustration, the percent sequence identity of a given nucleic acid or amino acid sequence, A, to, with, or against a given nucleic acid or amino acid sequence, B, (which can alternatively be phrased as a given nucleic acid or amino acid sequence, A that has a certain percent sequence identity to, with, or against a given nucleic acid or amino acid sequence, B) is calculated as follows:
[0046] 100 multiplied by (the fraction X / Y) where X is the number of nucleotides or amino acids scored as identical matches by a sequence alignment program (e.g., BLAST) in that program’s alignment of A and B, and where Y is the total number of nucleic acids in B. It will be appreciated that where the length of nucleic acid or amino acid sequence A is not equal to the length of nucleic acid or amino acid sequence B, the percent sequence identity of A to B will not equal the percent sequence identity of B to A.
[0047] As used herein, the term “inhibitory nucleic acid” or “inhibitory nucleic acid molecule” refers to a nucleic acid molecule that has sufficient complementarity to bind to a target nucleic acid molecule and inhibit or reduce (i.e., knock down) expression of the target (e.g., DSCAM). Exemplary inhibitory nucleic acid molecules are short hairpin RNAs (shRNA), anti-sense oligonucleotides (ASO), small interfering RNAs (siRNA), double-stranded RNAs (dsRNA), or microRNAs (miRNA). Inhibitory nucleic acid molecules may reduce expression of a target by 10% or more (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or more).
[0048] As used herein, the term “expression” refers to one or more of the following events: (1 ) production of an RNA molecule from a DNA sequence (e.g., by transcription), which may result in, for example, a pre-mRNA, mRNA, tRNA, or rRNA molecule; (2) processing of an RNA transcript (e.g., by splicing, editing, 5’ cap formation, and / or 3’ end processing), which may result in, for example, a pre- mRNA or an mRNA; (3) translation of an RNA into a polypeptide or protein; and (4) post-translational modification of a polypeptide or protein.
[0049] As used herein, the term “inhibit expression” means to reduce, down-regulate, suppress, block, lower, or stop expression of the gene. The expression product of a gene can be an RNA molecule transcribed from the gene (e.g., an mRNA) or a polypeptide translated from an mRNA transcribed from the gene. Typically, a reduction in the level of an mRNA results in a reduction in the level of a polypeptide translated therefrom. The level of expression may be determined using standard techniques for measuring mRNA or protein.
[0050] As used herein, the terms “subject” and “patient” refer to an animal (e.g., a mammal, such as a human). A subject to be treated according to the methods described herein may be one who has degeneration of the optic nerve (e.g., glaucoma).
[0051] As used herein, “treatment” and “treating” in reference to a disease or condition (e.g., cancer), refer to an approach for obtaining beneficial or desired results, e.g., clinical results. Beneficial or desired results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions; diminishment of extent of disease or condition; stabilized (i.e., not worsening) state of disease, disorder, or condition; preventing spread of disease or condition; delay or slowing the progress of the disease or condition; amelioration or palliation of the disease or condition; and remission (whether partial or total), whether detectable or undetectable. “Ameliorating” or “palliating” a disease or condition means that the extent and / or undesirable clinical manifestations of the disease, disorder, or condition are lessened and / or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder, as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.
[0052] As used herein, the terms “effective amount,” “therapeutically effective amount,” and a “sufficient amount” of a composition described herein refer to a quantity sufficient to, when administered to the subject, including a mammal, for example a human, effect beneficial or desired results, including clinical results, and, as such, an “effective amount” or synonym thereto depends upon the context in which it is being applied. The amount of a given composition described herein that will correspond to such an amount will vary depending upon various factors, such as the given inhibitory nucleic acid molecule, the pharmaceutical formulation, the route of administration, the type of disease or disorder, the identity of the subject (e.g., age, sex, weight) or host being treated, and the like, but can nevertheless be routinely determined by one skilled in the art. Also, as used herein, a “therapeutically effective amount” of a composition of the present disclosure is an amount which results in a beneficial or desired result in a subject as compared to a control. As defined herein, a therapeutically effective amount of a composition of the present disclosure may be readily determined by one of ordinary skill by routine methods known in the art. Dosage regimen may be adjusted to provide the optimum therapeutic response.
[0053] As used herein, the term “vector” refers to a nucleic acid, e.g., DNA or RNA, that may function as a vehicle for the delivery of a gene of interest into a cell (e.g., a mammalian cell, such as a human cell), tissue, organ, or organism, such as a patient undergoing treatment for a disease or condition described herein, for purposes of expressing an encoded transgene. Exemplary vectors useful in conjunction with the compositions and methods described herein are plasmids, DNA vectors, RNA vectors, virions, or other suitable replicon (e.g., viral vector).
[0054] As used herein, the term “DSCAM inhibitor” refers to a molecule that decreases the activity of DSCAM by binding to and inhibiting DSCAM. Exemplary DSCAM inhibitors include anti-DSCAM antibodies or antigen-binding fragments thereof, small molecules, or polypeptides.
[0055] DETAILED DESCRIPTION
[0056] Unless defined otherwise, all technical and scientific terms used have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Conventional methods are used for the procedures described herein, such as those provided in the art, and demonstrated in the Examples and various general references. Unless otherwise stated, nucleic acid sequences described herein are given, when read from left to right, in the 5’ to 3’ direction. Nucleic acid sequences may be provided as DNA or as RNA, as specified; disclosure of one necessarily defines the other, as is known to one of ordinary skill in the art.
[0057] The present invention is based, in part, on the discovery that Down Syndrome Cell Adhesion Molecule (DSCAM) inhibits donor RGC integration. DSCAM knockout in donor RGCs resulted in the spontaneous migration of a greater number of donor RGCs out of the subretinal space, compared to without knockout. These data indicate that donor cell integration can be improved by inhibiting DSCAM. DSCAM
[0058] Down Syndrome Cell Adhesion Molecule (DSCAM) (also known as CDH2) is a member of the immunoglobulin superfamily of cell adhesion molecules (Ig-CAMs). DSCAM mediates neuronal selfavoidance to preserve mosaic spacing in the retina during development, which may prevent donor RGCs from migrating toward their natural connecting points within the retina. Exemplary DSCAM mRNAs are shown below.
[0059] NR 073202.3 Homo sapiens DS cell adhesion molecule (DSCAM), transcript variant 3, non-coding RNA
[0060] AC T C GC C C GGC T C GC AGGC AGGGAAGGT T GGC AGAGGGAT C C AT GT GAC T GAGGC C GGAGC AC GGC AAAG ATGAGCCTGCCCGCCCGCCTGCTGCCTGGATGCGGAGGGTGAGGGCTGGCGCACGGGAGGCCGCTGGCTG CGCATTCTGGGCGCCGAGTGCCCGGGATGAGCTCACGCCCGCGTCTGCGGCTCTCTCCACCTGCCGACCT GCCGGGGGCCCACTGAGCTGACGGCGCACCTGGGCTCCGGCCGCAGCGTGGGGCGCGGCGCCCGGGAGCA GGTGTGCAGGAGCGCAGCGCGCGGCGAGCGCAGCCCTCGCTCCGGAGCCCGGCCGCGCCGCGTGCCCGGG CGGCTAGGCAGCGGCGGCGGCGGCGGCGGGCGGCGGGCGGGCGGCGGCCCCCGGGCAGGTGCCGAGCGGC GAGCGGAGCCGGGCCGGGCGGAGCGCGGGGGGCGAGGCCGGCGCGTCGCTCGCGGGAGGCCGGGGAGCGG CAGGGGCATGTGGATACTGGCTCTCTCCTTGTTCCAGAGCTTCGCGAATGTTTTCAGTGAAGACCTACAC TCCAGCCTCTACTTTGTCAATGCATCTCTGCAAGAGGTAGTGTTTGCCAGCACCACGGGGACTCTGGTGC CCTGCCCCGCAGCAGGCATCCCTCC T GT GAC T C T C AGAT GGTACCTAGCCACGGGC GAGGAGAT C T AC GA TGTCCCCGGGATCCGCCACGTCCACCCCAACGGCACTCTCCAAATTTTCCCCTTCCCTCCTTCAAGCTTC AGTACCTTAATCCATGATAATACTTATTATTGCACAGCT GAAAAT C C T T C AGGGAAAAT T AGAAGT C AGG ATGTCCACATCAAGGCTGTTTTACGGGAGCCCTATACAGTCCGTGTGGAGGACCAGAAAACCATGAGAGG CAATGTTGCGGTCTTCAAGTGCATTATCCCCTCCTCGGTGGAGGCGTACATCACTGTCGTCTCATGGGAG AAAGACACTGTTTCACTTGTCTCAGGATCTAGATTTCTCATCACATCCACGGGAGCCTTGTATATTAAAG AT GT AC AGAAT GAAGAT GGAT T GT AT AAC TACCGCTGCATCACGCGGCATCGATACACC GGAGAGAC GAG GCAGAGCAACAGCGCCAGACTTTTTGTATCAGACCCAGCGAACTCAGCCCCATCCATACTGGATGGGTTT GACCATCGCAAAGCCATGGCTGGGCAGCGTGTGGAGCTGCCTTGCAAAGCGCTCGGGCACCCTGAGCCAG ATTACCGCTGGCT GAAGGAC AAC AT GC C C C T GGAAC T T T C AGGGAGGT T C C AGAAGAC C GT GAC GGGGC T GCTCATTGAGAACATTCGCCCCTCGGACTCAGGCAGCTATGTTTGTGAAGTGTCCAACAGATACGGAACT GCTAAGGTGATAGGCCGCCTGTACGTGAAACAGCCACTGAAAGCCACCATCAGTCCCAGGAAGGTTAAAA GCAGCGTGGGTAGCCAAGTTTCCTTGTCCTGCAGCGTGACAGGAACTGAGGACCAGGAACTCTCCTGGTA C C GC AAT GGT GAAAT C C T C AAC C C T GGAAAAAAT GT GAGGAT C AC AGGGAT C AAC C AC GAAAAC C T T AT A ATGGATCACATGGTCAAAAGTGACGGGGGCGCATACCAGTGCTTTGTGCGCAAGGACAAGCTGTCCGCTC AAGACTATGTGCAGGTGGTCCTTGAAGATGGAACTCCCAAAATTATTTCTGCCTTTAGTGAAAAGGTGGT GAGTCCAGCAGAGCCGGTTTCCCTTATGTGCAACGTGAAGGGAACACCTTTGCCCACGATCACGTGGACC C T GGAC GAT GAC C C GAT T C T C AAGGGT GGC AGT C AC CGCATCAGC C AGAT GAT C AC GT C GGAGGGGAAC G TGGTCAGCTACCTGAACATCTCCAGCTCCCAGGTCCGGGACGGGGGAGTCTACCGCTGCACTGCCAACAA CTCGGCGGGAGTCGTCCTGTACCAGGCTCGAATAAACGTAAGAGGGCCTGCAAGCATTCGACCAATGAAA AACATCACAGCAATAGCAGGACGGGACACATACATTCACTGTCGTGTGATTGGCTATCCGTATTACTCCA TTAAATGGTACAAGAACTCTAACCTGCTTCCTTTCAACCACCGCCAAGTGGCATTTGAGAACAATGGAAC TCTTAAACTTTCAGATGTGCAAAAGGAAGTGGACGAGGGGGAGTACACGTGCAACGTGTTGGTTCAACCA CAACTCTCCACCAGCCAGAGCGTCCACGTGACCGTGAAAGTTCCGCCTTTCATACAACCCTTTGAGTTTC CAAGATTCTCCATTGGGCAGCGGGTCTTCATCCCCTGTGTTGTGGTCTCAGGGGACTTACCCATCACGAT C AC C T GGC AGAAGGAT GGC C GGC C AAT C C C T GGGAGC C T T GGGGT GAC C AT T GAC AAT AT T GAC T T C AC G AGC T C C T T GAGGAT T T C C AAT C T C T C GC T C AT GC AC AAT GGGAAT T AC AC C T GC AT AGC C C GGAAT GAGG CCGCCGCTGTGGAGCACCAAAGCCAGTTGATTGTCAGAGTTCCTCCCAAGTTTGTGGTTCAGCCACGGGA CCAGGACGGGATTTATGGCAAAGCAGTCATCCTCAATTGTTCTGCTGAGGGTTACCCTGTACCTACCATC GTGTGGAAATTCTCTAAAGGTGCTGGGGTTCCCCAGTTCCAGCCAATTGCCCTAAATGGCCGAATCCAAG TTCTCAGCAATGGGTCGTTGCTGATCAAGCATGTCGTGGAGGAAGACAGTGGCTACTACCTCTGCAAGGT CAGCAACGATGTGGGCGCAGACGTCAGCAAGTCCATGTACCTCACGGTTAAAATTCCTGCGATGATAACA T C C T AT C C AAAT AC TACCCTGGCCAC GC AGGGGC AGAAAAAGGAGAT GAGC TGCACGGCGCAT GGT GAGA AGCCCATTATAGTCCGCTGGGAGAAGGAGGACCGAATCATTAACCCTGAGATGGCCCGTTATCTTGTGTC C AC C AAGGAGGT GGGAGAAGAGGT GAT TTCTACTCT GC AGAT T T T GC C AAC T GT GAGAGAAGAT T C T GGT TTCTTTTCCTGCCATGCTATTAATTCTTATGGGGAGGACCGTGGAATAATTCAGCTCACAGTGCAAGAGC C C C C AGAC C C T C C C GAAAT T GAGAT C AAAGAT GT C AAAGC AC GCACAATTACGCT C AGGT GGAC C AT GGG GTTTGATGGAAACAGTCCCATCACAGGCTACGATATTGAATGCAAAAATAAATCAGACTCCTGGGATTCT GCTCAGAGAACCAAAGATGTTTCCCCTCAGCTGAACTCGGCCACCATCATTGATATCCACCCTTCCTCCA C C T AC AGC AT C C GC AT GT AC GC C AAGAAC C GGAT T GGC AAGAGC GAGC C C AGC AAC GAGC T C AC C AT C AC GGCGGACGAGGCAGCTCCTGATGGTCCACCTCAGGAAGTTCACCTGGAGCCTATATCATCTCAGAGCATC AGGGTCACATGGAAGGCTCCCAAGAAACATTTGCAAAATGGGATTATCCGTGGCTACCAAATAGGTTACC GAGAGTACAGCACTGGGGGTAACTTCCAATTCAACATTATCAGTGTCGACACCAGCGGGGACAGTGAGGT TTACACCCTGGACAACCTGAATAAGTTCACTCAGTACGGCCTGGTGGTGCAGGCCTGTAACCGGGCCGGC ACGGGGCCTTCTTCTCAGGAAATCATCACCACCACTCTCGAGGATGTGCCCAGTTACCCCCCCGAAAATG T C C AAGC C AT AGC AAC AT C AC C AGAAAGC AT AT C AAT AT C C T GGT C C AC AC T T T C C AAGGAAGC C T T GAA T GGAAT T C T C C AGGGGT T C AGAGT C AT T T AC T GGGC C AAC C T C AT GGAC GGAGAGC T GGGT GAGAT T AAA AAC AT C AC C AC C AC AC AGC C T T C AC T GGAGC T GGAC GGGC T GGAAAAGT AC AC C AAC T AC AGC AT C C AGG TGCTGGCCTTCACCCGC GC AGGAGAC GGGGT C AGGAGT GAGC AGAT C T T C AC C C GGAC C AAAGAGGAT GT TCCAGGTCCTCCCGCGGGTGTGAAGGCAGCGGCGGCCTCAGCCTCCATGGTCTTTGTGTCCTGGCTTCCC CCTCTCAAGCTGAACGGCATCATCCGAAAGTACACTGTATTCTGCTCCCACCCCTATCCCACAGTGATCA GCGAGTTTGAGGCCTCTCCCGACTCGTTTTCCTACAGAATTCCCAACCTGAGTAGGAATCGTCAGTACAG CGTCTGGGTGGTGGCTGTTACTTCAGCCGGAAGAGGCAACAGCAGTGAAATCATCACAGTCGAGCCACTA GC AAAAGC T C C T GC AC GAAT C C T GAC C T T C AGT GGGAC AGT GAC TACTCCATGGAT GAAAGAC AT T GT C T T GC C T T GT AAGGC T GT T GGGGAC C C T T C T C C T GC AGT C AAAT GGAT GAAAGAC AGT AAC GGGAC AC C C AG T C T AGT AAC GAT T GAT GGGC GGAGGAGC AT C T T T AGC AAC GGAAGC T T C AT T AT T C GC AC GGT GAAAGC A GAAGACTCCGGCTATTACAGCTGCATTGCCAATAACAACTGGGGATCTGATGAAATTATTTTAAACTTAC AAGTACAAGTTCCACCAGATCAGCCTCGGCTTACAGTCTCCAAGACCACGTCTTCCTCCATCACCCTTTC TTGGCTCCCTGGAGACAACGGGGGCAGCTCTATCAGAGGATACATACTGCAGTACTCCGAGGACAATAGT GAGCAGTGGGGGAGTTTTCCAATCAGCCCCAGCGAACGTTCCTATCGCTTGGAAAATCTCAAATGTGGGA C T T GGT AT AAGT T C AC AC T GAC AGC C C AAAAT GGAGT GGGC C C AGGGC GC AT AAGT GAAAT C AT AGAAGC AAAGAC C T T AGGAAAAGAGC CCCAGTTCT C AAAGGAGC AGGAGC TGTTTGCCAGCAT C AAC AC C AC AC GC GTGAGGCTGAACCTCATTGGCTGGAATGATGGCGGCTGCCCCATCACCTCCTTCACACTAGAGTACAGGC CCTTTGGGACCACAGTTTGGACCACAGCTCAGAGGACCTCTCTCTCCAAGTCCTACATCCTGTATGACCT GCAGGAAGCCACCTGGTATGAGCTGCAGATGCGGGTGTGCAACAGTGCGGGCTGCGCGGAGAAGCAGGCT AAAGAGGC TGC GAGAT GC AAAGAGT T T AGC T GAAAT GC T C AT GAGT AAGAAT AC C C GGAC T T C AGAT AC G T T AAGC AAGC AAC AGC AGAC C C T GC GAAT GC AC AT C GAC AT AC CCAGGGCTCAGCTTTTGATT GAAGAGA GAGAC AC GAT GGAGAC CATTGATGATCGCTCCACGGTTCTGTT GAC GGAT GC T GAC T T T GGAGAGGC AGC TAAGCAGAAGTCCCTGACGGTCACTCACACGGTCCATTACCAATCGGTGTCTCAGGCCACTGGGCCCTTA GT GGAT GT T T C AGAC GC T C GGC C GGGAAC GAAT C C C AC C AC C AGGAGGAAT GC C AAGGC T GGGC C C AC AG C GAGAAAC CGCTATGCCAGC C AGT GGAC C C T C AAC C GAC CCCACCCCACCATCTCAGCACACACCCTCAC C AC AGAC T GGAGGC TGC C AAC AC CCAGGGCTGCAGGAT C AGT AGAC AAAGAGAGC GAC AGT T AC AGC GT C AGC C C C T C GC AAGAC AC AGAT C GAGC AAGAAGC AGC AT GGT C T C C AC AGAAAGT GC CTCCTCCACTTACG AAGAAC TGGCCAGGGCCTAC GAAC AC GC C AAGAT GGAAGAGC AAC T GAGGC AC GC C AAGT T C AC CAT C AC GGAGTGCTTCATATCAGACACGTCATCGGAGCAGTTGACGGCAGGGACAAATGAGTACACGGACAGTCTG AC C T C C AGC AC C C C T T C C GAAT C GGGAAT C T GC AGGT T C AC T GC AT C T C C C C C C AAAC C T C AGGAT GGAG GAAGAGTAATGAATATGGCAGTTCCAAAGGCACATCGGCCAGGTGACCTCATACATTTGCCTCCATACCT TAGAAT GGAC T T T T T GT T AAAC C GAGGT GGT C CAGGC AC C AGC AGGGAC C T GAGC T TAGGAC AAGC AT GC T T GGAAC C T C AGAAAAGC C GGAC C C T GAAGC GCCCCACGGTCCT GGAGC CCATCCCGAT GGAAGC C GC C T CCTCCGCCTCCTCCACGAGAGAAGGACAGTCGTGGCAGCCGGGGGCCGTGGCCACATTACCTCAGCGGGA GGGAGC AGAGC T GGGAC AGGC AGC T AAAAT GAGC AGC T C C C AAGAAT C AC T GC T C GAC TCCCGGGGCCAT TTGAAAGGAAACAATCCTTACGCAAAATCTTACACCCTGGTATAACAGACAGCATGACTGGACAGCGGTT GTAAATACAATTCAAACAATTCAATCAAAGCTACCTTTTTTTTACGGAATTCCAATATTTATAATTAAAG AAAAT T GC C AAAAT AT AT TAAAAAAAAAAAAGAGAAAAT AC T GAAAC C AC AGAC AGT GC AAAGAC T C T C C TGCTTTTTTTCTGTCTGAGTGTGAGCTCCATCCGCCTGGGCATCTGATTTTTTGGGAAAGAAGTCCAGTT T T AT GAT C T T C AC AGGC T AT T GC AT T T T T AC T GAT T T T C T AC AAAAGT GC AT GGGGGGGAT T AAT T AAAC CTTCTGACTGGAAGTTCTATCACACAAGAGGCAAGAAAGAAAACAGGGTGGGTGGGAAATCAGCCTATTT GTGAATTTAAAAGGAACACCGATTTGCGGGCAGGGGAAAACTTCAGTCACGTTTGCACACCTTTCTTTCC CATTAGAAACCGGGTTCTCAATTTGGTCTTCTTTTGTTGTTAATTAGGATGAGTGCCGTCAGTGAAGGGG TGGGGGGAATCAATTTGGTTTTCTCTCTTGTTTCTTTTTTAATTTAATGAGACACTCTTTGCATTTTGTC TAAGCGAAATAAAAAAGAAAAGGTTGTCTGCCTTTATTTCCATGTCTGCTTCTCTCGTCTTCTGCCAGTG GCCTGGTCCTCCTTCCCATTGACACTTCTGTTTGGAAACACCAGGCCTGAACCCAGAGCCCAATTCAATA AAC C AGAGT C GAT AC T AAC AC C C T GAAC T C C T C AGGAAT C T C C AGGAAGC AC AAAGAAGGT GC AGC T C C T GC T C T C AAGC T GGAGAGGAC AAAAT GC AGGC T GGT C T C C AC C GC AAC CAGAGGC C AGC C C AAGT AT T C GA AGCCCGTCGCAAAGCTCTGCCCCTTGCCTGCCCATGGCCAGAGTTCAACTGACTGTGGCCTATGGGCCAA ATCCAGCCTCCTGCTGTTTTTTAAATAAAGTTTTATTGAAACAAGGCCACATGCACTATTTGCTATTGTC TATGGCTGCTTTCATGGCACAATGGTAGAGCTGAATAGTTGCAGCAGAGATGGTATAGCCCATGAAGCCT AAAAT AT T TAT T AC C T GGC C CAT T AC AGGAAAC AT T T GC C AGAC C C GT GC T C T GGAGT C T GAAAT GT AGC CCCAGCTTGCGTGACAAGGGGCAAGATCGTGCATCTTACCCTCCATGACTTTTCCTATCTCCACTATGCC TGGTATGCAAATTTGTGATAGACCATCTTAATAAACATTGCCTGAATCCTCTGTAACCAGAGGAAAGTGA TGTTCCTCTAAAATCTAAGTTTTTACTTTCCTTTCCCTCACTTTATCTCCCATGTGGCTCATCCTAAGAG AGAAT T T AC T C AT AAAT AGT C GGAAC T GC AT T C T T T AT C C C AC AAC C C T C AC AGGGT T T GC T T T AT GAAA GAGGATGTAATCCTCCCCTGGCTGCAACACTCCATTCCAGGCTCACTTCCATAAAATGGAAAGATAAACA GGTCTTTGTGTCAGAGATTTGGCATTAACCAGAAAACATGATCAAATATCCACAGCTGCTCAGTCTCCCA GGCTGAAGATTCTCTACAGGCTTCCATTAAGGCCACCAACATAGACTGGTGCCAGTTATTACCATCTTGG GAACATATTCAGAAATGTCTTTCCTTCCCTCCCTCCCTCCTTCTTTCCCATCCTTTCTTCCTTCTATTTA TTTTCCAGGCAGGCCCATTTGTCTGCTTAGATTCAGTGACACAGAATGGGTCCAGGACCATGTCAAGACC ACCTGCTGATGCTAGTGTTAGATGACTCCAGGAATGTGAGGTGTGCATCCATGGTTTCAGAATGTAATCC GTGTTGACGTGTACTGTTTGCATACTCTCAGACTGTTTTTTTTTTATGCAAAAGAAATGTTACTTTCTGG GGGAAAAAATTAAAAGTCTATCTTTCATCAACCTAAAACTTCTATATCCCCCAAACATAGAAGTTTACCT TTTTAACATTTTTCTCTCAACCTGTACAAAAATAAAAAAATTCTACATTA ( SEQ ID NO : 1 )
[0061] NM 001271534.3 Homo sapiens DS cell adhesion molecule (DSCAM), transcript variant 2, mRNA
[0062] AC T C GC C C GGC T C GC AGGC AGGGAAGGT T GGC AGAGGGAT C C AT GT GAC T GAGGC C GGAGC AC GGC AAAG ATGAGCCTGCCCGCCCGCCTGCTGCCTGGATGCGGAGGGTGAGGGCTGGCGCACGGGAGGCCGCTGGCTG CGCATTCTGGGCGCCGAGTGCCCGGGATGAGCTCACGCCCGCGTCTGCGGCTCTCTCCACCTGCCGACCT GCCGGGGGCCCACTGAGCTGACGGCGCACCTGGGCTCCGGCCGCAGCGTGGGGCGCGGCGCCCGGGAGCA GGTGTGCAGGAGCGCAGCGCGCGGCGAGCGCAGCCCTCGCTCCGGAGCCCGGCCGCGCCGCGTGCCCGGG CGGCTAGGCAGCGGCGGCGGCGGCGGCGGGCGGCGGGCGGGCGGCGGCCCCCGGGCAGGTGCCGAGCGGC GAGCGGAGCCGGGCCGGGCGGAGCGCGGGGGGCGAGGCCGGCGCGTCGCTCGCGGGAGGCCGGGGAGCGG CAGGGGCATGTGGATACTGGCTCTCTCCTTGTTCCAGAGCTTCGCGAATGTTTTCAGTGAAGACCTACAC TCCAGCCTCTACTTTGTCAATGCATCTCTGCAAGAGGTAGTGTTTGCCAGCACCACGGGGACTCTGGTGC CCTGCCCCGCAGCAGGCATCCCTCC T GT GAC T C T C AGAT GGTACCTAGCCACGGGC GAGGAGAT C T AC GA TGTCCCCGGGATCCGCCACGTCCACCCCAACGGCACTCTCCAAATTTTCCCCTTCCCTCCTTCAAGCTTC AGTACCTTAATCCATGATAATACTTATTATTGCACAGCT GAAAAT C C T T C AGGGAAAAT T AGAAGT C AGG ATGTCCACATCAAGGCTGTTTTACGGGAGCCCTATACAGTCCGTGTGGAGGACCAGAAAACCATGAGAGG CAATGTTGCGGTCTTCAAGTGCATTATCCCCTCCTCGGTGGAGGCGTACATCACTGTCGTCTCATGGGAG AAAGACACTGTTTCACTTGTCTCAGGATCTAGATTTCTCATCACATCCACGGGAGCCTTGTATATTAAAG AT GT AC AGAAT GAAGAT GGAT T GT AT AAC TACCGCTGCATCACGCGGCATCGATACACC GGAGAGAC GAG GCAGAGCAACAGCGCCAGACTTTTTGTATCAGACCCAGCGAACTCAGCCCCATCCATACTGGATGGGTTT GACCATCGCAAAGCCATGGCTGGGCAGCGTGTGGAGCTGCCTTGCAAAGCGCTCGGGCACCCTGAGCCAG ATTACCGCTGGCT GAAGGAC AAC AT GC C C C T GGAAC T T T C AGGGAGGT T C C AGAAGAC C GT GAC GGGGC T GCTCATTGAGAACATTCGCCCCTCGGACTCAGGCAGCTATGTTTGTGAAGTGTCCAACAGATACGGAACT GCTAAGGTGATAGGCCGCCTGTACGTGAAACAGCCACTGAAAGCCACCATCAGTCCCAGGAAGGTTAAAA GCAGCGTGGGTAGCCAAGTTTCCTTGTCCTGCAGCGTGACAGGAACTGAGGACCAGGAACTCTCCTGGTA C C GC AAT GGT GAAAT C C T C AAC C C T GGAAAAAAT GT GAGGAT C AC AGGGAT C AAC C AC GAAAAC C T T AT A ATGGATCACATGGTCAAAAGTGACGGGGGCGCATACCAGTGCTTTGTGCGCAAGGACAAGCTGTCCGCTC AAGACTATGTGCAGGTGGTCCTTGAAGATGGAACTCCCAAAATTATTTCTGCCTTTAGTGAAAAGGTGGT GAGTCCAGCAGAGCCGGTTTCCCTTATGTGCAACGTGAAGGGAACACCTTTGCCCACGATCACGTGGACC C T GGAC GAT GAC C C GAT T C T C AAGGGT GGC AGT C AC CGCATCAGC C AGAT GAT C AC GT C GGAGGGGAAC G TGGTCAGCTACCTGAACATCTCCAGCTCCCAGGTCCGGGACGGGGGAGTCTACCGCTGCACTGCCAACAA CTCGGCGGGAGTCGTCCTGTACCAGGCTCGAATAAACGTAAGAGGGCCTGCAAGCATTCGACCAATGAAA AACATCACAGCAATAGCAGGACGGGACACATACATTCACTGTCGTGTGATTGGCTATCCGTATTACTCCA TTAAATGGTACAAGAACTCTAACCTGCTTCCTTTCAACCACCGCCAAGTGGCATTTGAGAACAATGGAAC TCTTAAACTTTCAGATGTGCAAAAGGAAGTGGACGAGGGGGAGTACACGTGCAACGTGTTGGTTCAACCA CAACTCTCCACCAGCCAGAGCGTCCACGTGACCGTGAAAGTTCCGCCTTTCATACAACCCTTTGAGTTTC CAAGATTCTCCATTGGGCAGCGGGTCTTCATCCCCTGTGTTGTGGTCTCAGGGGACTTACCCATCACGAT C AC C T GGC AGAAGGAT GGC C GGC C AAT C C C T GGGAGC C T T GGGGT GAC C AT T GAC AAT AT T GAC T T C AC G AGC T C C T T GAGGAT T T C C AAT C T C T C GC T C AT GC AC AAT GGGAAT T AC AC C T GC AT AGC C C GGAAT GAGG CCGCCGCTGTGGAGCACCAAAGCCAGTTGATTGTCAGAGTTCCTCCCAAGTTTGTGGTTCAGCCACGGGA CCAGGACGGGATTTATGGCAAAGCAGTCATCCTCAATTGTTCTGCTGAGGGTTACCCTGTACCTACCATC GTGTGGAAATTCTCTAAAGGTGCTGGGGTTCCCCAGTTCCAGCCAATTGCCCTAAATGGCCGAATCCAAG TTCTCAGCAATGGGTCGTTGCTGATCAAGCATGTCGTGGAGGAAGACAGTGGCTACTACCTCTGCAAGGT CAGCAACGATGTGGGCGCAGACGTCAGCAAGTCCATGTACCTCACGGTTAAAATTCCTGCGATGATAACA T C C T AT C C AAAT AC TACCCTGGCCAC GC AGGGGC AGAAAAAGGAGAT GAGC TGCACGGCGCAT GGT GAGA AGCCCATTATAGTCCGCTGGGAGAAGGAGGACCGAATCATTAACCCTGAGATGGCCCGTTATCTTGTGTC C AC C AAGGAGGT GGGAGAAGAGGT GAT TTCTACTCT GC AGAT T T T GC C AAC T GT GAGAGAAGAT T C T GGT TTCTTTTCCTGCCATGCTATTAATTCTTATGGGGAGGACCGTGGAATAATTCAGCTCACAGTGCAAGAGC C C C C AGAC C C T C C C GAAAT T GAGAT C AAAGAT GT C AAAGC AC GCACAATTACGCT C AGGT GGAC C AT GGG GTTTGATGGAAACAGTCCCATCACAGGCTACGATATTGAATGCAAAAATAAATCAGACTCCTGGGATTCT GCTCAGAGAACCAAAGATGTTTCCCCTCAGCTGAACTCGGCCACCATCATTGATATCCACCCTTCCTCCA C C T AC AGC AT C C GC AT GT AC GC C AAGAAC C GGAT T GGC AAGAGC GAGC C C AGC AAC GAGC T C AC C AT C AC GGCGGACGAGGCAGCTCCTGATGGTCCACCTCAGGAAGTTCACCTGGAGCCTATATCATCTCAGAGCATC AGGGTCACATGGAAGGCTCCCAAGAAACATTTGCAAAATGGGATTATCCGTGGCTACCAAATAGGTTACC GAGAGTACAGCACTGGGGGTAACTTCCAATTCAACATTATCAGTGTCGACACCAGCGGGGACAGTGAGGT TTACACCCTGGACAACCTGAATAAGTTCACTCAGTACGGCCTGGTGGTGCAGGCCTGTAACCGGGCCGGC ACGGGGCCTTCTTCTCAGGAAATCATCACCACCACTCTCGAGGATGTGCCCAGTTACCCCCCCGAAAATG T C C AAGC C AT AGC AAC AT C AC C AGAAAGC AT AT C AAT AT C C T GGT C C AC AC T T T C C AAGGAAGC C T T GAA T GGAAT T C T C C AGGGGT T C AGAGT C AT T T AC T GGGC C AAC C T C AT GGAC GGAGAGC T GGGT GAGAT T AAA AAC AT C AC C AC C AC AC AGC C T T C AC T GGAGC T GGAC GGGC T GGAAAAGT AC AC C AAC T AC AGC AT C C AGG TGCTGGCCTTCACCCGC GC AGGAGAC GGGGT C AGGAGT GAGC AGAT C T T C AC C C GGAC C AAAGAGGAT GT TCCAGGTCCTCCCGCGGGTGTGAAGGCAGCGGCGGCCTCAGCCTCCATGGTCTTTGTGTCCTGGCTTCCC CCTCTCAAGCTGAACGGCATCATCCGAAAGTACACTGTATTCTGCTCCCACCCCTATCCCACAGTGATCA GCGAGTTTGAGGCCTCTCCCGACTCGTTTTCCTACAGAATTCCCAACCTGAGTAGGAATCGTCAGTACAG CGTCTGGGTGGTGGCTGTTACTTCAGCCGGAAGAGGCAACAGCAGTGAAATCATCACAGTCGAGCCACTA GC AAAAGC T C C T GC AC GAAT C C T GAC C T T C AGT GGGAC AGT GAC TACTCCATGGAT GAAAGAC AT T GT C T T GC C T T GT AAGGC T GT T GGGGAC C C T T C T C C T GC AGT C AAAT GGAT GAAAGAC AGT AAC GGGAC AC C C AG T C T AGT AAC GAT T GAT GGGC GGAGGAGC AT C T T T AGC AAC GGAAGC T T C AT T AT T C GC AC GGT GAAAGC A GAAGACTCCGGCTATTACAGCTGCATTGCCAATAACAACTGGGGATCTGATGAAATTATTTTAAACTTAC AAGTACAAGTTCCACCAGATCAGCCTCGGCTTACAGTCTCCAAGACCACGTCTTCCTCCATCACCCTTTC TTGGCTCCCTGGAGACAACGGGGGCAGCTCTATCAGAGGATACATACTGCAGTACTCCGAGGACAATAGT GAGCAGTGGGGGAGTTTTCCAATCAGCCCCAGCGAACGTTCCTATCGCTTGGAAAATCTCAAATGTGGGA C T T GGT AT AAGT T C AC AC T GAC AGC C C AAAAT GGAGT GGGC C C AGGGC GC AT AAGT GAAAT C AT AGAAGC AAAGAC C T T AGGAAAAGAGC CCCAGTTCT C AAAGGAGC AGGAGC TGTTTGCCAGCAT C AAC AC C AC AC GC GTGAGGCTGAACCTCATTGGCTGGAATGATGGCGGCTGCCCCATCACCTCCTTCACACTAGAGTACAGGC CCTTTGGGACCACAGTTTGGACCACAGCTCAGAGGACCTCTCTCTCCAAGTCCTACATCCTGTATGACCT GCAGGAAGCCACCTGGTATGAGCTGCAGATGCGGGTGTGCAACAGTGCGGGCTGCGCGGAGAAGCAGGCC AACTTCGCTACGCTGAACTACGATGGCAGTACAATTCCTCCACTCATTAAGTCAGTTGTCCAAAACGAAG AAGGGCTGACGACCAACGAGGGGCTCAAGATGCTGGTGACCATCTCCTGTATCCTGGTGGGGGTCTTGCT GCTGTTTGTGCTCCTGCTGGTTGTGCGGAGGAGGCGGCGGGAGCAGAGGCTAAAGAGGCTGCGAGATGCA AAGAGT T T AGC T GAAAT GC T C AT GAGT AAGAAT AC C C GGAC T T C AGAT AC GT T AAGC AAGC AAC AGC AGA C C C T GC GAAT GC AC AT C GAC AT AC CCAGGGCTCAGCTTTTGATT GAAGAGAGAGAC AC GAT GGAGAC CAT TGATGATCGCTCCACGGTTCTGTT GAC GGAT GC T GAC T T T GGAGAGGC AGC T AAGC AGAAGT C C C T GAC G GTCACTCACACGGTCCATTACCAATCGGTGTCTCAGGCCACTGGGCCCTTAGTGGATGTTTCAGACGCTC GGC C GGGAAC GAAT C C C AC C AC C AGGAGGAAT GC C AAGGC TGGGCCCACAGC GAGAAAC CGCTATGCCAG C C AGT GGAC C C T C AAC C GAC CCCACCCCACCATCTCAGCACACACCCTCAC C AC AGAC T GGAGGC T GC C A AC AC C C AGGGC T GC AGGAT C AGT AGAC AAAGAGAGC GAC AGT T AC AGC GT C AGC C C C T C GC AAGAC AC AG AT C GAGC AAGAAGC AGC AT GGT C T C C AC AGAAAGT GC CTCCTCCACTTAC GAAGAAC TGGCCAGGGCCTA C GAAC AC GC C AAGAT GGAAGAGC AAC T GAGGC AC GC C AAGT T C AC CAT C AC GGAGT GC T T C AT AT C AGAC AC GT CAT C GGAGC AGT T GAC GGC AGGGAC AAAT GAGT AC AC GGAC AGT C T GAC CTCCAGCACCCCTTCCG AATCGGGAATCTGCAGGTTCACTGCATCTCCCCCCAAACCTCAGGATGGAGGAAGAGTAATGAATATGGC AGTTCCAAAGGCACATCGGCCAGGTGGTCCAGGCACCAGCAGGGACCTGAGCTTAGGACAAGCATGCTTG GAACCTCAGAAAAGCCGGACCCTGAAGCGCCCCACGGTCCTGGAGCCCATCCCGATGGAAGCCGCCTCCT CCGCCTCCTCCACGAGAGAAGGACAGTCGTGGCAGCCGGGGGCCGTGGCCACATTACCTCAGCGGGAGGG AGC AGAGC T GGGAC AGGC AGC T AAAAT GAGC AGC T C C C AAGAAT C AC T GC T C GAC TCCCGGGGCCATTTG AAAGGAAACAATCCTTACGCAAAATCTTACACCCTGGTATAACAGACAGCATGACTGGACAGCGGTTGTA AATACAATTCAAACAATTCAATCAAAGCTACCTTTTTTTTACGGAATTCCAATATTTATAATTAAAGAAA AT T GC C AAAAT AT AT TAAAAAAAAAAAAGAGAAAAT AC T GAAAC C AC AGAC AGT GC AAAGAC T C T C C T GC TTTTTTTCTGTCTGAGTGTGAGCTCCATCCGCCTGGGCATCTGATTTTTTGGGAAAGAAGTCCAGTTTTA TGATCTTCACAGGCTATTGCATTTTTACTGATTTTCTACAAAAGTGCATGGGGGGGATTAATTAAACCTT CTGACTGGAAGTTCTATCACACAAGAGGCAAGAAAGAAAACAGGGTGGGTGGGAAATCAGCCTATTTGTG AAT T T AAAAGGAAC AC C GAT T T GC GGGC AGGGGAAAAC TTCAGTCACGTTTGCACACCTTTCTTTCCCAT TAGAAACCGGGTTCTCAATTTGGTCTTCTTTTGTTGTTAATTAGGATGAGTGCCGTCAGTGAAGGGGTGG GGGGAATCAATTTGGTTTTCTCTCTTGTTTCTTTTTTAATTTAATGAGACACTCTTTGCATTTTGTCTAA GCGAAATAAAAAAGAAAAGGTTGTCTGCCTTTATTTCCATGTCTGCTTCTCTCGTCTTCTGCCAGTGGCC TGGTCCTCCTTCCCATTGACACTTCTGTTTGGAAACACCAGGCCTGAACCCAGAGCCCAATTCAATAAAC C AGAGT C GAT AC T AAC AC C C T GAAC T C C T C AGGAAT C T C C AGGAAGC AC AAAGAAGGT GC AGC T C C T GC T C T C AAGC T GGAGAGGAC AAAAT GC AGGC T GGT C T C C AC C GC AAC CAGAGGC C AGC C C AAGT AT T C GAAGC CCGTCGCAAAGCTCTGCCCCTTGCCTGCCCATGGCCAGAGTTCAACTGACTGTGGCCTATGGGCCAAATC CAGCCTCCTGCTGTTTTTTAAATAAAGTTTTATTGAAACAAGGCCACATGCACTATTTGCTATTGTCTAT GGCTGCTTTCATGGCACAATGGTAGAGCTGAATAGTTGCAGCAGAGATGGTATAGCCCATGAAGCCTAAA ATATTTATTACCTGGCCCATTACAGGAAACATTTGCCAGACCCGTGCTCTGGAGTCTGAAATGTAGCCCC AGCTTGCGTGACAAGGGGCAAGATCGTGCATCTTACCCTCCATGACTTTTCCTATCTCCACTATGCCTGG TATGCAAATTTGTGATAGACCATCTTAATAAACATTGCCTGAATCCTCTGTAACCAGAGGAAAGTGATGT TCCTCTAAAATCTAAGTTTTTACTTTCCTTTCCCTCACTTTATCTCCCATGTGGCTCATCCTAAGAGAGA AT T T AC T C AT AAAT AGT C GGAAC T GC AT T C T T T AT C C C AC AAC C C T C AC AGGGT T T GC T T T AT GAAAGAG GATGTAATCCTCCCCTGGCTGCAACACTCCATTCCAGGCTCACTTCCATAAAATGGAAAGATAAACAGGT C T T T GT GT C AGAGAT T T GGC AT T AAC C AGAAAAC AT GAT C AAAT AT C C AC AGC T GC T C AGT C T C C C AGGC T GAAGAT T C T C T AC AGGC T T C C AT T AAGGC C AC C AAC AT AGAC T GGT GC C AGT T AT T AC C AT C T T GGGAA CATATTCAGAAATGTCTTTCCTTCCCTCCCTCCCTCCTTCTTTCCCATCCTTTCTTCCTTCTATTTATTT TCCAGGCAGGCCCATTTGTCTGCTTAGATTCAGTGACACAGAATGGGTCCAGGACCATGTCAAGACCACC TGCTGATGCTAGTGTTAGATGACTCCAGGAATGTGAGGTGTGCATCCATGGTTTCAGAATGTAATCCGTG TTGACGTGTACTGTTTGCATACTCTCAGACTGTTTTTTTTTTATGCAAAAGAAATGTTACTTTCTGGGGG AAAAAAT T AAAAGT C T AT C T T T C AT C AAC C T AAAAC T T C T AT AT C C C C C AAAC AT AGAAGT T T AC C T T T T TAACATTTTTCTCTCAACCTGTACAAAAATAAAAAAATTCTACATTA ( SEQ ID NO : 2 )
[0063] NM 001389.5 Homo sapiens DS cell adhesion molecule (DSCAM), transcript variant 1, mRNA
[0064] AC T C GC C C GGC T C GC AGGC AGGGAAGGT T GGC AGAGGGAT C C AT GT GAC T GAGGC C GGAGC AC GGC AAAG ATGAGCCTGCCCGCCCGCCTGCTGCCTGGATGCGGAGGGTGAGGGCTGGCGCACGGGAGGCCGCTGGCTG CGCATTCTGGGCGCCGAGTGCCCGGGATGAGCTCACGCCCGCGTCTGCGGCTCTCTCCACCTGCCGACCT GCCGGGGGCCCACTGAGCTGACGGCGCACCTGGGCTCCGGCCGCAGCGTGGGGCGCGGCGCCCGGGAGCA GGTGTGCAGGAGCGCAGCGCGCGGCGAGCGCAGCCCTCGCTCCGGAGCCCGGCCGCGCCGCGTGCCCGGG CGGCTAGGCAGCGGCGGCGGCGGCGGCGGGCGGCGGGCGGGCGGCGGCCCCCGGGCAGGTGCCGAGCGGC GAGCGGAGCCGGGCCGGGCGGAGCGCGGGGGGCGAGGCCGGCGCGTCGCTCGCGGGAGGCCGGGGAGCGG CAGGGGCATGTGGATACTGGCTCTCTCCTTGTTCCAGAGCTTCGCGAATGTTTTCAGTGAAGACCTACAC TCCAGCCTCTACTTTGTCAATGCATCTCTGCAAGAGGTAGTGTTTGCCAGCACCACGGGGACTCTGGTGC CCTGCCCCGCAGCAGGCATCCCTCC T GT GAC T C T C AGAT GGTACCTAGCCACGGGC GAGGAGAT C T AC GA TGTCCCCGGGATCCGCCACGTCCACCCCAACGGCACTCTCCAAATTTTCCCCTTCCCTCCTTCAAGCTTC AGTACCTTAATCCATGATAATACTTATTATTGCACAGCT GAAAAT C C T T C AGGGAAAAT T AGAAGT CAGG ATGTCCACATCAAGGCTGTTTTACGGGAGCCCTATACAGTCCGTGTGGAGGACCAGAAAACCATGAGAGG CAATGTTGCGGTCTTCAAGTGCATTATCCCCTCCTCGGTGGAGGCGTACATCACTGTCGTCTCATGGGAG AAAGACACTGTTTCACTTGTCTCAGGATCTAGATTTCTCATCACATCCACGGGAGCCTTGTATATTAAAG AT GT AC AGAAT GAAGAT GGAT T GT AT AAC TACCGCTGCATCACGCGGCATCGATACACC GGAGAGAC GAG GCAGAGCAACAGCGCCAGACTTTTTGTATCAGACCCAGCGAACTCAGCCCCATCCATACTGGATGGGTTT GACCATCGCAAAGCCATGGCTGGGCAGCGTGTGGAGCTGCCTTGCAAAGCGCTCGGGCACCCTGAGCCAG ATTACCGCTGGCT GAAGGAC AAC AT GC C C C T GGAAC T T T C AGGGAGGT T C C AGAAGAC C GT GAC GGGGC T GCTCATTGAGAACATTCGCCCCTCGGACTCAGGCAGCTATGTTTGTGAAGTGTCCAACAGATACGGAACT GCTAAGGTGATAGGCCGCCTGTACGTGAAACAGCCACTGAAAGCCACCATCAGTCCCAGGAAGGTTAAAA GCAGCGTGGGTAGCCAAGTTTCCTTGTCCTGCAGCGTGACAGGAACTGAGGACCAGGAACTCTCCTGGTA C C GC AAT GGT GAAAT C C T C AAC C C T GGAAAAAAT GT GAGGAT C AC AGGGAT C AAC C AC GAAAAC C T T AT A ATGGATCACATGGTCAAAAGTGACGGGGGCGCATACCAGTGCTTTGTGCGCAAGGACAAGCTGTCCGCTC AAGACTATGTGCAGGTGGTCCTTGAAGATGGAACTCCCAAAATTATTTCTGCCTTTAGTGAAAAGGTGGT GAGTCCAGCAGAGCCGGTTTCCCTTATGTGCAACGTGAAGGGAACACCTTTGCCCACGATCACGTGGACC C T GGAC GAT GAC C C GAT T C T C AAGGGT GGC AGT C AC CGCATCAGC C AGAT GAT C AC GT C GGAGGGGAAC G TGGTCAGCTACCTGAACATCTCCAGCTCCCAGGTCCGGGACGGGGGAGTCTACCGCTGCACTGCCAACAA CTCGGCGGGAGTCGTCCTGTACCAGGCTCGAATAAACGTAAGAGGGCCTGCAAGCATTCGACCAATGAAA AACATCACAGCAATAGCAGGACGGGACACATACATTCACTGTCGTGTGATTGGCTATCCGTATTACTCCA TTAAATGGTACAAGAACTCTAACCTGCTTCCTTTCAACCACCGCCAAGTGGCATTTGAGAACAATGGAAC TCTTAAACTTTCAGATGTGCAAAAGGAAGTGGACGAGGGGGAGTACACGTGCAACGTGTTGGTTCAACCA CAACTCTCCACCAGCCAGAGCGTCCACGTGACCGTGAAAGTTCCGCCTTTCATACAACCCTTTGAGTTTC CAAGATTCTCCATTGGGCAGCGGGTCTTCATCCCCTGTGTTGTGGTCTCAGGGGACTTACCCATCACGAT C AC C T GGC AGAAGGAT GGC C GGC C AAT C C C T GGGAGC C T T GGGGT GAC C AT T GAC AAT AT T GAC T T C AC G AGC T C C T T GAGGAT T T C C AAT C T C T C GC T C AT GC AC AAT GGGAAT T AC AC C T GC AT AGC C C GGAAT GAGG CCGCCGCTGTGGAGCACCAAAGCCAGTTGATTGTCAGAGTTCCTCCCAAGTTTGTGGTTCAGCCACGGGA CCAGGACGGGATTTATGGCAAAGCAGTCATCCTCAATTGTTCTGCTGAGGGTTACCCTGTACCTACCATC GTGTGGAAATTCTCTAAAGGTGCTGGGGTTCCCCAGTTCCAGCCAATTGCCCTAAATGGCCGAATCCAAG TTCTCAGCAATGGGTCGTTGCTGATCAAGCATGTCGTGGAGGAAGACAGTGGCTACTACCTCTGCAAGGT CAGCAACGATGTGGGCGCAGACGTCAGCAAGTCCATGTACCTCACGGTTAAAATTCCTGCGATGATAACA T C C T AT C C AAAT AC TACCCTGGCCAC GC AGGGGC AGAAAAAGGAGAT GAGC TGCACGGCGCAT GGT GAGA AGCCCATTATAGTCCGCTGGGAGAAGGAGGACCGAATCATTAACCCTGAGATGGCCCGTTATCTTGTGTC C AC C AAGGAGGT GGGAGAAGAGGT GAT TTCTACTCT GC AGAT T T T GC C AAC T GT GAGAGAAGAT T C T GGT TTCTTTTCCTGCCATGCTATTAATTCTTATGGGGAGGACCGTGGAATAATTCAGCTCACAGTGCAAGAGC C C C C AGAC C C T C C C GAAAT T GAGAT C AAAGAT GT C AAAGC AC GCACAATTACGCT C AGGT GGAC C AT GGG GTTTGATGGAAACAGTCCCATCACAGGCTACGATATTGAATGCAAAAATAAATCAGACTCCTGGGATTCT GCTCAGAGAACCAAAGATGTTTCCCCTCAGCTGAACTCGGCCACCATCATTGATATCCACCCTTCCTCCA C C T AC AGC AT C C GC AT GT AC GC C AAGAAC C GGAT T GGC AAGAGC GAGC C C AGC AAC GAGC T C AC C AT C AC GGCGGACGAGGCAGCTCCTGATGGTCCACCTCAGGAAGTTCACCTGGAGCCTATATCATCTCAGAGCATC AGGGTCACATGGAAGGCTCCCAAGAAACATTTGCAAAATGGGATTATCCGTGGCTACCAAATAGGTTACC GAGAGTACAGCACTGGGGGTAACTTCCAATTCAACATTATCAGTGTCGACACCAGCGGGGACAGTGAGGT TTACACCCTGGACAACCTGAATAAGTTCACTCAGTACGGCCTGGTGGTGCAGGCCTGTAACCGGGCCGGC ACGGGGCCTTCTTCTCAGGAAATCATCACCACCACTCTCGAGGATGTGCCCAGTTACCCCCCCGAAAATG T C C AAGC C AT AGC AAC AT C AC C AGAAAGC AT AT C AAT AT C C T GGT C C AC AC T T T C C AAGGAAGC C T T GAA T GGAAT T C T C CAGGGGT T CAGAGT CAT T T AC T GGGC C AAC C T CAT GGAC GGAGAGC T GGGT GAGAT T AAA AAC AT C AC C AC C AC AC AGC C T T C AC T GGAGC T GGAC GGGC T GGAAAAGT AC AC C AAC T AC AGC AT C C AGG TGCTGGCCTTCACCCGC GC AGGAGAC GGGGT CAGGAGT GAGC AGAT C T T C AC C C GGAC C AAAGAGGAT GT TCCAGGTCCTCCCGCGGGTGTGAAGGCAGCGGCGGCCTCAGCCTCCATGGTCTTTGTGTCCTGGCTTCCC CCTCTCAAGCTGAACGGCATCATCCGAAAGTACACTGTATTCTGCTCCCACCCCTATCCCACAGTGATCA GCGAGTTTGAGGCCTCTCCCGACTCGTTTTCCTACAGAATTCCCAACCTGAGTAGGAATCGTCAGTACAG CGTCTGGGTGGTGGCTGTTACTTCAGCCGGAAGAGGCAACAGCAGTGAAATCATCACAGTCGAGCCACTA GC AAAAGC T C C T GC AC GAAT C C T GAC C T T C AGT GGGAC AGT GAC TACTCCATGGAT GAAAGAC AT T GT C T T GC C T T GT AAGGC T GT T GGGGAC C C T T C T C C T GC AGT C AAAT GGAT GAAAGAC AGT AAC GGGAC AC C C AG T C T AGT AAC GAT T GAT GGGC GGAGGAGC AT C T T T AGC AAC GGAAGC T T C AT T AT T C GC AC GGT GAAAGC A GAAGACTCCGGCTATTACAGCTGCATTGCCAATAACAACTGGGGATCTGATGAAATTATTTTAAACTTAC AAGTACAAGTTCCACCAGATCAGCCTCGGCTTACAGTCTCCAAGACCACGTCTTCCTCCATCACCCTTTC TTGGCTCCCTGGAGACAACGGGGGCAGCTCTATCAGAGGATACATACTGCAGTACTCCGAGGACAATAGT GAGCAGTGGGGGAGTTTTCCAATCAGCCCCAGCGAACGTTCCTATCGCTTGGAAAATCTCAAATGTGGGA C T T GGT AT AAGT T C AC AC T GAC AGC C C AAAAT GGAGT GGGC C C AGGGC GC AT AAGT GAAAT C AT AGAAGC AAAGAC C T T AGGAAAAGAGC CCCAGTTCT C AAAGGAGC AGGAGC TGTTTGCCAGCAT C AAC AC C AC AC GC GTGAGGCTGAACCTCATTGGCTGGAATGATGGCGGCTGCCCCATCACCTCCTTCACACTAGAGTACAGGC CCTTTGGGACCACAGTTTGGACCACAGCTCAGAGGACCTCTCTCTCCAAGTCCTACATCCTGTATGACCT GCAGGAAGCCACCTGGTATGAGCTGCAGATGCGGGTGTGCAACAGTGCGGGCTGCGCGGAGAAGCAGGCC AACTTCGCTACGCTGAACTACGATGGCAGTACAATTCCTCCACTCATTAAGTCAGTTGTCCAAAACGAAG AAGGGCTGACGACCAACGAGGGGCTCAAGATGCTGGTGACCATCTCCTGTATCCTGGTGGGGGTCTTGCT GCTGTTTGTGCTCCTGCTGGTTGTGCGGAGGAGGCGGCGGGAGCAGAGGCTAAAGAGGCTGCGAGATGCA AAGAGT T T AGC T GAAAT GC T C AT GAGT AAGAAT AC C C GGAC T T C AGAT AC GT T AAGC AAGC AAC AGC AGA C C C T GC GAAT GC AC AT C GAC AT AC CCAGGGCTCAGCTTTTGATT GAAGAGAGAGAC AC GAT GGAGAC CAT TGATGATCGCTCCACGGTTCTGTT GAC GGAT GC T GAC T T T GGAGAGGC AGC T AAGC AGAAGT C C C T GAC G GTCACTCACACGGTCCATTACCAATCGGTGTCTCAGGCCACTGGGCCCTTAGTGGATGTTTCAGACGCTC GGC C GGGAAC GAAT C C C AC C AC C AGGAGGAAT GC C AAGGC TGGGCCCACAGC GAGAAAC CGCTATGCCAG C C AGT GGAC C C T C AAC C GAC CCCACCCCACCATCTCAGCACACACCCTCAC C AC AGAC T GGAGGC T GC C A AC AC C C AGGGC T GC AGGAT C AGT AGAC AAAGAGAGC GAC AGT T AC AGC GT C AGC C C C T C GC AAGAC AC AG AT C GAGC AAGAAGC AGC AT GGT C T C C AC AGAAAGT GC CTCCTCCACTTAC GAAGAAC TGGCCAGGGCCTA C GAAC AC GC C AAGAT GGAAGAGC AAC T GAGGC AC GC C AAGT T C AC CAT C AC GGAGT GC T T C AT AT C AGAC AC GT CAT C GGAGC AGT T GAC GGC AGGGAC AAAT GAGT AC AC GGAC AGT C T GAC CTCCAGCACCCCTTCCG AATCGGGAATCTGCAGGTTCACTGCATCTCCCCCCAAACCTCAGGATGGAGGAAGAGTAATGAATATGGC AGTTCCAAAGGCACATCGGCCAGGTGACCTCATACATTTGCCTCCATACCTTAGAATGGACTTTTTGTTA AAC C GAGGT GGT C C AGGC AC C AGC AGGGAC C T GAGC T T AGGAC AAGC AT GC T T GGAAC C T C AGAAAAGC C GGACCCTGAAGCGCCCCACGGTCCTGGAGCCCATCCCGATGGAAGCCGCCTCCTCCGCCTCCTCCACGAG AGAAGGACAGTCGTGGCAGCCGGGGGCCGTGGCCACATTACCTCAGCGGGAGGGAGCAGAGCTGGGACAG GC AGC T AAAAT GAGC AGC T C C C AAGAAT C AC T GC T C GAC TCCCGGGGCCATTT GAAAGGAAAC AAT C C T T ACGCAAAATCTTACACCCTGGTATAACAGACAGCATGACTGGACAGCGGTTGTAAATACAATTCAAACAA TTCAATCAAAGCTACCTTTTTTTTACGGAATTCCAATATTTATAATTAAAGAAAATTGCCAAAATATATT AAAAAAAAAAAAGAGAAAAT AC T GAAAC C AC AGAC AGT GC AAAGAC TCTCCTGCTTTTTTTCTGTCT GAG TGTGAGCTCCATCCGCCTGGGCATCTGATTTTTTGGGAAAGAAGTCCAGTTTTATGATCTTCACAGGCTA TTGCATTTTTACTGATTTTCTACAAAAGTGCATGGGGGGGATTAATTAAACCTTCTGACTGGAAGTTCTA T C AC AC AAGAGGC AAGAAAGAAAAC AGGGT GGGT GGGAAAT CAGCCTATT T GT GAAT T T AAAAGGAAC AC CGATTTGCGGGCAGGGGAAAACTTCAGTCACGTTTGCACACCTTTCTTTCCCATTAGAAACCGGGTTCTC AATTTGGTCTTCTTTTGTTGTTAATTAGGATGAGTGCCGTCAGTGAAGGGGTGGGGGGAATCAATTTGGT TTTCTCTCTTGTTTCTTTTTTAATTTAATGAGACACTCTTTGCATTTTGTCTAAGCGAAATAAAAAAGAA AAGGTTGTCTGCCTTTATTTCCATGTCTGCTTCTCTCGTCTTCTGCCAGTGGCCTGGTCCTCCTTCCCAT T GAC AC TTCTGTTT GGAAAC AC C AGGC C T GAAC C C AGAGC C C AAT T C AAT AAAC C AGAGT C GAT AC T AAC AC C C T GAAC T C C T C AGGAAT C T C C AGGAAGC AC AAAGAAGGT GC AGC TCCTGCTCT C AAGC T GGAGAGGA CAAAATGCAGGCTGGTCTCCACCGCAACCAGAGGCCAGCCCAAGTATTCGAAGCCCGTCGCAAAGCTCTG CCCCTTGCCTGCCCATGGCCAGAGTTCAACTGACTGTGGCCTATGGGCCAAATCCAGCCTCCTGCTGTTT TTTAAATAAAGTTTTATTGAAACAAGGCCACATGCACTATTTGCTATTGTCTATGGCTGCTTTCATGGCA C AAT GGT AGAGC T GAAT AGT T GC AGC AGAGAT GGT AT AGC C C AT GAAGC C T AAAAT AT T T AT T AC C T GGC CCATTACAGGAAACATTTGCCAGACCCGTGCTCTGGAGTCTGAAATGTAGCCCCAGCTTGCGTGACAAGG GGCAAGATCGTGCATCTTACCCTCCATGACTTTTCCTATCTCCACTATGCCTGGTATGCAAATTTGTGAT AGACCATCTTAATAAACATTGCCTGAATCCTCTGTAACCAGAGGAAAGTGATGTTCCTCTAAAATCTAAG TTTTTACTTTCCTTTCCCTCACTTTATCTCCCATGTGGCTCATCCTAAGAGAGAATTTACTCATAAATAG TCGGAACTGCATTCTTTATCCCACAACCCTCACAGGGTTTGCTTTATGAAAGAGGATGTAATCCTCCCCT GGCTGCAACACTCCATTCCAGGCTCACTTCCATAAAATGGAAAGATAAACAGGTCTTTGTGTCAGAGATT T GGC AT T AAC C AGAAAAC AT GAT C AAAT AT CCACAGCTGCTCAGTCTCCCAGGCT GAAGAT T C T C T AC AG GCTTCCATTAAGGCCACCAACATAGACTGGTGCCAGTTATTACCATCTTGGGAACATATTCAGAAATGTC TTTCCTTCCCTCCCTCCCTCCTTCTTTCCCATCCTTTCTTCCTTCTATTTATTTTCCAGGCAGGCCCATT TGTCTGCTTAGATTCAGTGACACAGAATGGGTCCAGGACCATGTCAAGACCACCTGCTGATGCTAGTGTT AGATGACTCCAGGAATGTGAGGTGTGCATCCATGGTTTCAGAATGTAATCCGTGTTGACGTGTACTGTTT GCATACTCTCAGACTGTTTTTTTTTTATGCAAAAGAAATGTTACTTTCTGGGGGAAAAAATTAAAAGTCT ATCTTTCATCAACCTAAAACTTCTATATCCCCCAAACATAGAAGTTTACCTTTTTAACATTTTTCTCTCA ACCTGTACAAAAATAAAAAAATTCTACATTA ( SEQ ID NO : 3 )
[0065] XM 017028281.2 PREDICTED: Homo sapiens DS cell adhesion molecule (DSCAM), transcript variant X1 , mRNA
[0066] TTTCCTCTATTTCAGGATCTAGATTTCTCATCACATCCACGGGAGCCTTGTATATTAAAGATGTACAGAA T GAAGAT GGAT T GT AT AAC TACCGCTGCATCACGCGGCATCGATACACC GGAGAGAC GAGGC AGAGC AAC AGCGCCAGACTTTTTGTATCAGACCCAGCGAACTCAGCCCCATCCATACTGGATGGGTTTGACCATCGCA AAGCCATGGCTGGGCAGCGTGTGGAGCTGCCTTGCAAAGCGCTCGGGCACCCTGAGCCAGATTACCGCTG GC T GAAGGAC AAC AT GC C C C T GGAAC T T T C AGGGAGGT T C C AGAAGAC C GT GAC GGGGCTGCTCATT GAG AACATTCGCCCCTCGGACTCAGGCAGCTATGTTTGTGAAGTGTCCAACAGATACGGAACTGCTAAGGTGA TAGGCCGCCTGTACGTGAAACAGCCACTGAAAGCCACCATCAGTCCCAGGAAGGTTAAAAGCAGCGTGGG TAGCCAAGTTTCCTTGTCCTGCAGCGTGACAGGAACTGAGGACCAGGAACTCTCCTGGTACCGCAATGGT GAAAT C C T C AAC C C T GGAAAAAAT GT GAGGAT C AC AGGGAT C AAC C AC GAAAAC CTTATAATGGATCACA TGGTCAAAAGTGACGGGGGCGCATACCAGTGCTTTGTGCGCAAGGACAAGCTGTCCGCTCAAGACTATGT GCAGGTGGTCCTTGAAGATGGAACTCCCAAAATTATTTCTGCCTTTAGTGAAAAGGTGGTGAGTCCAGCA GAGCCGGTTTCCCTTATGTGCAACGTGAAGGGAACACCTTTGCCCACGATCACGTGGACCCTGGACGATG ACCCGATTCTCAAGGGTGGCAGTCACCGCATCAGCCAGATGATCACGTCGGAGGGGAACGTGGTCAGCTA CCTGAACATCTCCAGCTCCCAGGTCCGGGACGGGGGAGTCTACCGCTGCACTGCCAACAACTCGGCGGGA GTCGTCCTGTACCAGGCTCGAATAAACGTAAGAGGGCCTGCAAGCATTCGACCAATGAAAAACATCACAG CAATAGCAGGACGGGACACATACATTCACTGTCGTGTGATTGGCTATCCGTATTACTCCATTAAATGGTA CAAGAACTCTAACCTGCTTCCTTTCAACCACCGCCAAGTGGCATTTGAGAACAATGGAACTCTTAAACTT TCAGATGTGCAAAAGGAAGTGGACGAGGGGGAGTACACGTGCAACGTGTTGGTTCAACCACAACTCTCCA CCAGCCAGAGCGTCCACGTGACCGTGAAAGTTCCGCCTTTCATACAACCCTTTGAGTTTCCAAGATTCTC CATTGGGCAGCGGGTCTTCATCCCCTGTGTTGTGGTCTCAGGGGACTTACCCATCACGATCACCTGGCAG AAGGAT GGCCGGCCAATCCCT GGGAGC C T T GGGGT GAC C AT T GAC AAT AT T GAC T T C AC GAGC T C C T T GA GGAT T T C C AAT C T C T C GC T C AT GC AC AAT GGGAAT T AC AC C T GC AT AGC C C GGAAT GAGGC C GC C GC T GT GGAGCACCAAAGCCAGTTGATTGTCAGAGTTCCTCCCAAGTTTGTGGTTCAGCCACGGGACCAGGACGGG ATTTATGGCAAAGCAGTCATCCTCAATTGTTCTGCTGAGGGTTACCCTGTACCTACCATCGTGTGGAAAT TCTCTAAAGGTGCTGGGGTTCCCCAGTTCCAGCCAATTGCCCTAAATGGCCGAATCCAAGTTCTCAGCAA TGGGTCGTTGCTGATCAAGCATGTCGTGGAGGAAGACAGTGGCTACTACCTCTGCAAGGTCAGCAACGAT GTGGGCGCAGACGTCAGCAAGTCCATGTACCTCACGGTTAAAATTCCTGCGATGATAACATCCTATCCAA ATACTACCCTGGCCAC GC AGGGGC AGAAAAAGGAGAT GAGC TGCACGGCGCAT GGT GAGAAGC C CAT TAT AGT C C GC T GGGAGAAGGAGGAC C GAAT CAT T AAC C C T GAGAT GGCCCGTTATCTTGTGTCCAC C AAGGAG GTGGGAGAAGAGGTGATTTCTACTCTGCAGATTTTGCCAACTGTGAGAGAAGATTCTGGTTTCTTTTCCT GC C AT GC T AT T AAT T C T T AT GGGGAGGAC C GT GGAAT AAT T C AGC T C AC AGT GC AAGAGC C C C C AGAC C C TCCCGAAATTGAGATCAAAGATGTCAAAGCACGCACAATTACGCTCAGGTGGACCATGGGGTTTGATGGA AAC AGT C CCATCACAGGCTACGATATT GAAT GC AAAAAT AAAT C AGAC TCCTGGGATTCTGCT C AGAGAA C C AAAGAT GT T T C C C C T C AGC T GAAC T C GGC C AC C AT C AT T GAT AT C C AC C C T T C C T C C AC C T AC AGC AT CCGCATGTACGC C AAGAAC C GGAT T GGC AAGAGC GAGC C C AGC AAC GAGC TC AC CATC AC GGC GGAC GAG GCAGCTCCTGATGGTCCACCTCAGGAAGTTCACCTGGAGCCTATATCATCTCAGAGCATCAGGGTCACAT GGAAGGCTCCCAAGAAACATTTGCAAAATGGGATTATCCGTGGCTACCAAATAGGTTACCGAGAGTACAG CACTGGGGGTAACTTCCAATTCAACATTATCAGTGTCGACACCAGCGGGGACAGTGAGGTTTACACCCTG GACAACCTGAATAAGTTCACTCAGTACGGCCTGGTGGTGCAGGCCTGTAACCGGGCCGGCACGGGGCCTT CTTCTCAGGAAATCATCACCACCACTCTCGAGGATGTGCCCAGTTACCCCCCCGAAAATGTCCAAGCCAT AGCAACATCACCAGAAAGCATATCAATATCCTGGTCCACACTTTCCAAGGAAGCCTTGAATGGAATTCTC C AGGGGT T C AGAGT C AT T T AC T GGGC C AAC C T C AT GGAC GGAGAGC T GGGT GAGAT T AAAAAC AT C AC C A C C AC AC AGC C T T C AC T GGAGC T GGAC GGGC T GGAAAAGT AC AC C AAC T AC AGC AT C C AGGT GC T GGC C T T C AC C C GC GC AGGAGAC GGGGT C AGGAGT GAGC AGAT C T T C AC C C GGAC C AAAGAGGAT GT T CCAGGTCCT CCCGCGGGTGTGAAGGCAGCGGCGGCCTCAGCCTCCATGGTCTTTGTGTCCTGGCTTCCCCCTCTCAAGC TGAACGGCATCATCCGAAAGTACACTGTATTCTGCTCCCACCCCTATCCCACAGTGATCAGCGAGTTTGA GGCCTCTCCCGACTCGTTTTCCTACAGAATTCCCAACCTGAGTAGGAATCGTCAGTACAGCGTCTGGGTG GT GGC T GT T AC T T C AGC C GGAAGAGGC AAC AGC AGT GAAAT C AT C AC AGT C GAGC C AC T AGC AAAAGC T C CTGCACGAATCCTGACCTTCAGTGGGACAGTGACTACTCCATGGATGAAAGACATTGTCTTGCCTTGTAA GGCTGTTGGGGACCCTTCTCCTGCAGTCAAATGGATGAAAGACAGTAACGGGACACCCAGTCTAGTAACG ATTGATGGGC GGAGGAGC AT C T T T AGC AAC GGAAGC TTCATTATTCGCAC GGT GAAAGC AGAAGAC T C C G GCTATTACAGCTGCATTGCCAATAACAACTGGGGATCTGATGAAATTATTTTAAACTTACAAGTACAAGT TCCACCAGATCAGCCTCGGCTTACAGTCTCCAAGACCACGTCTTCCTCCATCACCCTTTCTTGGCTCCCT GGAGACAACGGGGGCAGCTCTATCAGAGGATACATACTGCAGTACTCCGAGGACAATAGTGAGCAGTGGG GGAGTTTTCCAATCAGCCCCAGCGAACGTTCCTATCGCTTGGAAAATCTCAAATGTGGGACTTGGTATAA GTTCACACTGACAGCCCAAAATGGAGTGGGCCCAGGGCGCATAAGTGAAATCATAGAAGCAAAGACCTTA GGAAAAGAGC CCCAGTTCT C AAAGGAGC AGGAGC TGTTTGCCAGCAT C AAC AC C AC AC GC GT GAGGC T GA ACCTCATTGGCTGGAATGATGGCGGCTGCCCCATCACCTCCTTCACACTAGAGTACAGGCCCTTTGGGAC C AC AGT T T GGAC C AC AGC T C AGAGGAC CTCTCTCTC C AAGT C CTACATCCTGTAT GAC C T GC AGGAAGC C ACCTGGTATGAGCTGCAGATGCGGGTGTGCAACAGTGCGGGCTGCGCGGAGAAGCAGGCCAACTTCGCTA CGCTGAACTACGATGGCAGTACAATTCCTCCACTCATTAAGTCAGTTGTCCAAAACGAAGAAGGGCTGAC GACCAACGAGGGGCTCAAGATGCTGGTGACCATCTCCTGTATCCTGGTGGGGGTCTTGCTGCTGTTTGTG CTCCTGCTGGTTGTGC GGAGGAGGC GGC GGGAGC AGAGGC T AAAGAGGC TGC GAGAT GC AAAGAGT T TAG C T GAAAT GC T C AT GAGT AAGAAT AC C C GGAC T T C AGAT AC GT T AAGC AAGC AAC AGC AGAC C C T GC GAAT GC AC AT C GAC AT AC CCAGGGCTCAGCTTTTGATT GAAGAGAGAGAC AC GAT GGAGAC CATTGATGATCGC TCCACGGTTCTGTT GAC GGAT GC T GAC T T T GGAGAGGC AGC T AAGC AGAAGT C C C T GAC GGTCACTCACA CGGTCCATTACCAATCGGTGTCTCAGGCCACTGGGCCCTTAGTGGATGTTTCAGACGCTCGGCCGGGAAC GAAT C C C AC C AC C AGGAGGAAT GC C AAGGC TGGGCCCACAGC GAGAAAC CGCTATGCCAGC C AGT GGAC C C T C AAC C GAC CCCACCCCACCATCTCAGCACACACCCTCAC C AC AGAC T GGAGGC TGC C AAC AC C C AGGG C T GC AGGAT C AGT AGAC AAAGAGAGC GAC AGT T AC AGC GT C AGC C C C T C GC AAGAC AC AGAT C GAGC AAG AAGC AGC AT GGT C T C C AC AGAAAGT GC C T C C T C C AC T T AC GAAGAAC T GGC C AGGGC C T AC GAAC AC GC C AAGAT GGAAGAGC AAC T GAGGC AC GC C AAGT T C AC C AT C AC GGAGT GC T T C AT AT C AGAC AC GT C AT C GG AGC AGT T GAC GGC AGGGAC AAAT GAGT AC AC GGAC AGT C T GAC CTCCAGCACCCCTTCC GAAT C GGGAAT C T GC AGGT T C AC T GC AT C T C C C C C CAAAC C T C AGGAT GGAGGAAGAGTAAT GAAT AT GGC AGT T C CAAAG GCACATCGGCCAGGTGACCTCATACATTTGCCTCCATACCTTAGAATGGACTTTTTGTTAAACCGAGGTG GT C C AGGC AC C AGC AGGGAC C T GAGC T T AGGAC AAGC AT GC T T GGAAC C T C AGAAAAGC C GGAC C C T GAA GCGCCCCACGGTCCTGGAGCCCATCCCGATGGAAGCCGCCTCCTCCGCCTCCTCCACGAGAGAAGGACAG TCGTGGCAGCCGGGGGCCGTGGCCACATTACCTCAGCGGGAGGGAGCAGAGCTGGGACAGGCAGCTAAAA T GAGC AGC T C C C AAGAAT C AC T GC T C GAC TCCCGGGGCCATTT GAAAGGAAAC AAT C C T T AC GC AAAAT C TTACACCCTGGTATAACAGACAGCATGACTGGACAGCGGTTGTAAATACAATTCAAACAATTCAATCAAA GC T AC C T T T T T T T T AC GGAAT T C C AAT AT T T AT AAT T AAAGAAAAT T GC C AAAAT AT AT T AAAAAAAAAA AAGAGAAAATACTGAAACCACAGACAGTGCAAAGACTCTCCTGCTTTTTTTCTGTCTGAGTGTGAGCTCC ATCCGCCTGGGCATCTGATTTTTTGGGAAAGAAGTCCAGTTTTATGATCTTCACAGGCTATTGCATTTTT ACTGATTTTCTACAAAAGTGCATGGGGGGGATTAATTAAACCTTCTGACTGGAAGTTCTATCACACAAGA GGC AAGAAAGAAAACAGGGT GGGT GGGAAAT CAGCCTATT T GT GAAT T T AAAAGGAAC AC CGATTTGCGG GCAGGGGAAAACTTCAGTCACGTTTGCACACCTTTCTTTCCCATTAGAAACCGGGTTCTCAATTTGGTCT TCTTTTGTTGTTAATTAGGATGAGTGCCGTCAGTGAAGGGGTGGGGGGAATCAATTTGGTTTTCTCTCTT GTTTCTTTTTTAATTTAATGAGACACTCTTTGCATTTTGTCTAAGCGAAATAAAAAAGAAAAGGTTGTCT GCCTTTA ( SEQ ID NO : 4 )
[0067] XM 054333308.1 PREDICTED: Homo sapiens DS cell adhesion molecule (DSCAM), transcript variant X1 , mRNA
[0068] TTTCCTCTATTTCAGGATCTAGATTTCTCATCACATCCACGGGAGCCTTGTATATTAAAGATGTACAGAA T GAAGAT GGAT T GT AT AAC TACCGCTGCATCACGCGGCATCGATACACC GGAGAGAC GAGGC AGAGC AAC AGCGCCAGACTTTTTGTATCAGACCCAGCGAACTCAGCCCCATCCATACTGGATGGGTTTGACCATCGCA AAGCCATGGCTGGGCAGCGTGTGGAGCTGCCTTGCAAAGCGCTCGGGCACCCTGAGCCAGATTACCGCTG GC T GAAGGAC AAC AT GC C C C T GGAAC T T T C AGGGAGGT T C C AGAAGAC C GT GAC GGGGCTGCTCATT GAG AACATTCGCCCCTCGGACTCAGGCAGCTATGTTTGTGAAGTGTCCAACAGATACGGAACTGCTAAGGTGA TAGGCCGCCTGTACGTGAAACAGCCACTGAAAGCCACCATCAGTCCCAGGAAGGTTAAAAGCAGCGTGGG TAGCCAAGTTTCCTTGTCCTGCAGCGTGACAGGAACTGAGGACCAGGAACTCTCCTGGTACCGCAATGGT GAAAT C C T C AAC C C T GGAAAAAAT GT GAGGAT C AC AGGGAT C AAC C AC GAAAAC CTTATAATGGATCACA TGGTCAAAAGTGACGGGGGCGCATACCAGTGCTTTGTGCGCAAGGACAAGCTGTCCGCTCAAGACTATGT GCAGGTGGTCCTTGAAGATGGAACTCCCAAAATTATTTCTGCCTTTAGTGAAAAGGTGGTGAGTCCAGCA GAGCCGGTTTCCCTTATGTGCAACGTGAAGGGAACACCTTTGCCCACGATCACGTGGACCCTGGACGATG ACCCGATTCTCAAGGGTGGCAGTCACCGCATCAGCCAGATGATCACGTCGGAGGGGAACGTGGTCAGCTA CCTGAACATCTCCAGCTCCCAGGTCCGGGACGGGGGAGTCTACCGCTGCACTGCCAACAACTCGGCGGGA GTCGTCCTGTACCAGGCTCGAATAAACGTAAGAGGGCCTGCAAGCATTCGACCAATGAAAAACATCACAG CAATAGCAGGACGGGACACATACATTCACTGTCGTGTGATTGGCTATCCGTATTACTCCATTAAATGGTA CAAGAACTCTAACCTGCTTCCTTTCAACCACCGCCAAGTGGCATTTGAGAACAATGGAACTCTTAAACTT TCAGATGTGCAAAAGGAAGTGGACGAGGGGGAGTACACGTGCAACGTGTTGGTTCAACCACAACTCTCCA CCAGCCAGAGCGTCCACGTGACCGTGAAAGTTCCGCCTTTCATACAACCCTTTGAGTTTCCAAGATTCTC CATTGGGCAGCGGGTCTTCATCCCCTGTGTTGTGGTCTCAGGGGACTTACCCATCACGATCACCTGGCAG AAGGAT GGCCGGCCAATCCCT GGGAGC C T T GGGGT GAC C AT T GAC AAT AT T GAC T T C AC GAGC T C C T T GA GGAT T T C C AAT C T C T C GC T C AT GC AC AAT GGGAAT T AC AC C T GC AT AGC C C GGAAT GAGGC C GC C GC T GT GGAGCACCAAAGCCAGTTGATTGTCAGAGTTCCTCCCAAGTTTGTGGTTCAGCCACGGGACCAGGACGGG ATTTATGGCAAAGCAGTCATCCTCAATTGTTCTGCTGAGGGTTACCCTGTACCTACCATCGTGTGGAAAT TCTCTAAAGGTGCTGGGGTTCCCCAGTTCCAGCCAATTGCCCTAAATGGCCGAATCCAAGTTCTCAGCAA TGGGTCGTTGCTGATCAAGCATGTCGTGGAGGAAGACAGTGGCTACTACCTCTGCAAGGTCAGCAACGAT GTGGGCGCAGACGTCAGCAAGTCCATGTACCTCACGGTTAAAATTCCTGCGATGATAACATCCTATCCAA ATACTACCCTGGCCAC GC AGGGGC AGAAAAAGGAGAT GAGC TGCACGGCGCAT GGT GAGAAGC C CAT TAT AGT C C GC T GGGAGAAGGAGGAC C GAAT CAT T AAC C C T GAGAT GGCCCGTTATCTTGTGTCCAC C AAGGAG GTGGGAGAAGAGGTGATTTCTACTCTGCAGATTTTGCCAACTGTGAGAGAAGATTCTGGTTTCTTTTCCT GC C AT GC T AT T AAT T C T T AT GGGGAGGAC C GT GGAAT AAT T C AGC T C AC AGT GC AAGAGC C C C C AGAC C C TCCCGAAATTGAGATCAAAGATGTCAAAGCACGCACAATTACGCTCAGGTGGACCATGGGGTTTGATGGA AAC AGT C CCATCACAGGCTACGATATT GAAT GC AAAAAT AAAT C AGAC TCCTGGGATTCTGCT C AGAGAA C C AAAGAT GT T T C C C C T C AGC T GAAC T C GGC C AC C AT C AT T GAT AT C C AC C C T T C C T C C AC C T AC AGC AT CCGCATGTACGC C AAGAAC C GGAT T GGC AAGAGC GAGC C C AGC AAC GAGC TC AC CATC AC GGC GGAC GAG GCAGCTCCTGATGGTCCACCTCAGGAAGTTCACCTGGAGCCTATATCATCTCAGAGCATCAGGGTCACAT GGAAGGCTCCCAAGAAACATTTGCAAAATGGGATTATCCGTGGCTACCAAATAGGTTACCGAGAGTACAG CACTGGGGGTAACTTCCAATTCAACATTATCAGTGTCGACACCAGCGGGGACAGTGAGGTTTACACCCTG GACAACCTGAATAAGTTCACTCAGTACGGCCTGGTGGTGCAGGCCTGTAACCGGGCCGGCACGGGGCCTT CTTCTCAGGAAATCATCACCACCACTCTCGAGGATGTGCCCAGTTACCCCCCCGAAAATGTCCAAGCCAT AGCAACATCACCAGAAAGCATATCAATATCCTGGTCCACACTTTCCAAGGAAGCCTTGAATGGAATTCTC C AGGGGT T C AGAGT C AT T T AC T GGGC C AAC C T C AT GGAC GGAGAGC T GGGT GAGAT T AAAAAC AT C AC C A C C AC AC AGC C T T C AC T GGAGC T GGAC GGGC T GGAAAAGT AC AC C AAC T AC AGC AT C C AGGT GC T GGC C T T C AC C C GC GC AGGAGAC GGGGT CAGGAGT GAGC AGAT C T T C AC C C GGAC C AAAGAGGAT GT T CCAGGTCCT CCCGCGGGTGTGAAGGCAGCGGCGGCCTCAGCCTCCATGGTCTTTGTGTCCTGGCTTCCCCCTCTCAAGC TGAACGGCATCATCCGAAAGTACACTGTATTCTGCTCCCACCCCTATCCCACAGTGATCAGCGAGTTTGA GGCCTCTCCCGACTCGTTTTCCTACAGAATTCCCAACCTGAGTAGGAATCGTCAGTACAGCGTCTGGGTG GT GGC T GT T AC T T C AGC C GGAAGAGGC AAC AGC AGT GAAAT C AT C AC AGT C GAGC C AC T AGC AAAAGC T C CTGCACGAATCCTGACCTTCAGTGGGACAGTGACTACTCCATGGATGAAAGACATTGTCTTGCCTTGTAA GGCTGTTGGGGACCCTTCTCCTGCAGTCAAATGGATGAAAGACAGTAACGGGACACCCAGTCTAGTAACG ATTGATGGGC GGAGGAGC AT C T T T AGC AAC GGAAGC TTCATTATTCGCAC GGT GAAAGC AGAAGAC T C C G GCTATTACAGCTGCATTGCCAATAACAACTGGGGATCTGATGAAATTATTTTAAACTTACAAGTACAAGT TCCACCAGATCAGCCTCGGCTTACAGTCTCCAAGACCACGTCTTCCTCCATCACCCTTTCTTGGCTCCCT GGAGACAACGGGGGCAGCTCTATCAGAGGATACATACTGCAGTACTCCGAGGACAATAGTGAGCAGTGGG GGAGTTTTCCAATCAGCCCCAGCGAACGTTCCTATCGCTTGGAAAATCTCAAATGTGGGACTTGGTATAA GTTCACACTGACAGCCCAAAATGGAGTGGGCCCAGGGCGCATAAGTGAAATCATAGAAGCAAAGACCTTA GGAAAAGAGC CCCAGTTCT C AAAGGAGC AGGAGC TGTTTGCCAGCAT C AAC AC C AC AC GC GT GAGGC T GA ACCTCATTGGCTGGAATGATGGCGGCTGCCCCATCACCTCCTTCACACTAGAGTACAGGCCCTTTGGGAC C AC AGT T T GGAC C AC AGC T C AGAGGAC CTCTCTCTC C AAGT C CTACATCCTGTAT GAC C T GC AGGAAGC C ACCTGGTATGAGCTGCAGATGCGGGTGTGCAACAGTGCGGGCTGCGCGGAGAAGCAGGCCAACTTCGCTA CGCTGAACTACGATGGCAGTACAATTCCTCCACTCATTAAGTCAGTTGTCCAAAACGAAGAAGGGCTGAC GACCAACGAGGGGCTCAAGATGCTGGTGACCATCTCCTGTATCCTGGTGGGGGTCTTGCTGCTGTTTGTG CTCCTGCTGGTTGTGC GGAGGAGGC GGC GGGAGC AGAGGC T AAAGAGGC TGC GAGAT GC AAAGAGT T TAG C T GAAAT GC T C AT GAGT AAGAAT AC C C GGAC T T C AGAT AC GT T AAGC AAGC AAC AGC AGAC C C T GC GAAT GC AC AT C GAC AT AC CCAGGGCTCAGCTTTTGATT GAAGAGAGAGAC AC GAT GGAGAC CATTGATGATCGC TCCACGGTTCTGTT GAC GGAT GC T GAC T T T GGAGAGGC AGC T AAGC AGAAGT C C C T GAC GGTCACTCACA CGGTCCATTACCAATCGGTGTCTCAGGCCACTGGGCCCTTAGTGGATGTTTCAGACGCTCGGCCGGGAAC GAAT C C C AC C AC C AGGAGGAAT GC C AAGGC TGGGCCCACAGC GAGAAAC CGCTATGCCAGC C AGT GGAC C C T C AAC C GAC CCCACCCCACCATCTCAGCACACACCCTCAC C AC AGAC T GGAGGC TGC C AAC AC C C AGGG C T GC AGGAT C AGT AGAC AAAGAGAGC GAC AGT T AC AGC GT C AGC C C C T C GC AAGAC AC AGAT C GAGC AAG AAGC AGC AT GGT C T C C AC AGAAAGT GC C T C C T C C AC T T AC GAAGAAC T GGC C AGGGC C T AC GAAC AC GC C AAGAT GGAAGAGC AAC T GAGGC AC GC C AAGT T C AC C AT C AC GGAGT GC T T C AT AT C AGAC AC GT C AT C GG AGC AGT T GAC GGC AGGGAC AAAT GAGT AC AC GGAC AGT C T GAC CTCCAGCACCCCTTCC GAAT C GGGAAT C T GC AGGT T C AC T GC AT C T C C C C C C AAAC C T C AGGAT GGAGGAAGAGT AAT GAAT AT GGC AGT T C C AAAG GCACATCGGCCAGGTGACCTCATACATTTGCCTCCATACCTTAGAATGGACTTTTTGTTAAACCGAGGTG GT C C AGGC AC C AGC AGGGAC C T GAGC T T AGGAC AAGC AT GC T T GGAAC C T C AGAAAAGC C GGAC C C T GAA GCGCCCCACGGTCCTGGAGCCCATCCCGATGGAAGCCGCCTCCTCCGCCTCCTCCACGAGAGAAGGACAG TCGTGGCAGCCGGGGGCCGTGGCCACATTACCTCAGCGGGAGGGAGCAGAGCTGGGACAGGCAGCTAAAA T GAGC AGC T C C C AAGAAT C AC T GC T C GAC TCCCGGGGCCATTT GAAAGGAAAC AAT C C T T AC GC AAAAT C TTACACCCTGGTATAACAGACAGCATGACTGGACAGCGGTTGTAAATACAATTCAAACAATTCAATCAAA GC T AC C T T T T T T T T AC GGAAT T C C AAT AT T T AT AAT T AAAGAAAAT T GC C AAAAT AT AT T AAAAAAAAAA AAGAGAAAATACTGAAACCACAGACAGTGCAAAGACTCTCCTGCTTTTTTTCTGTCTGAGTGTGAGCTCC ATCCGCCTGGGCATCTGATTTTTTGGGAAAGAAGTCCAGTTTTATGATCTTCACAGGCTATTGCATTTTT ACTGATTTTCTACAAAAGTGCATGGGGGGGATTAATTAAACCTTCTGACTGGAAGTTCTATCACACAAGA GGC AAGAAAGAAAAC AGGGT GGGT GGGAAAT CAGCCTATT T GT GAAT T T AAAAGGAAC AC CGATTTGCGG GCAGGGGAAAACTTCAGTCACGTTTGCACACCTTTCTTTCCCATTAGAAACCGGGTTCTCAATTTGGTCT TCTTTTGTTGTTAATTAGGATGAGTGCCGTCAGTGAAGGGGTGGGGGGAATCAATTTGGTTTTCTCTCTT GTTTCTTTTTTAATTTAATGAGACACTCTTTGCATTTTGTCTAAGCGAAATAAAAAAGAAAAGGTTGTCT GCCTTTATTTCCATGTCTGCTTCTCTCGTCTTCTGCCAGTGGCCTGGTCCTCCTTCCCATTGACACTTCT GT T T GGAAAC AC C AGGC C T GAAC C C AGAGC C C AAT T C AAT AAAC C AGAGT C GAT AC T AAC AC C C T GAAC T C C T C AGGAAT C T C C AGGAAGC AC AAAGAAGGT GC AGC TCCTGCTCT C AAGC T GGAGAGGAC AAAAT GC AG GCTGGTCTCCACCGCAACCAGAGGCCAGCCCAAGTATTCGAAGCCCGTCGCAAAGCTCTGCCCCTTGCCT GCCCATGGCCAGAGTTCAACTGACTGTGGCCTATGGGCCAAATCCAGCCTCCTGCTGTTTTTTAAATAAA GTTTTATTGAAACAAGGCCACATGCACTATTTGCTATTGTCTATGGCTGCTTTCATGGCACAATGGTAGA GC T GAAT AGT T GC AGC AGAGAT GGT AT AGC C C AT GAAGC C T AAAAT AT T T AT T AC C T GGC C C AT T AC AGG AAAC AT T T GC C AGAC C C GT GC T C T GGAGT C T GAAAT GT AGC C C C AGC T T GC GT GAC AAGGGGC AAGAT C G TGCATCTTACCCTCCATGACTTTTCCTATCTCCACTATGCCTGGTATGCAAATTTGTGATAGACCATCTT AATAAACATTGCCTGAATCCTCTGTAACCAGAGGAAAGTGATGTTCCTCTAAAATCTAAGTTTTTACTTT CCTTTCCCTCACTTTATCTCCCATGTGGCTCATCCTAAGAGAGAATTTACTCATAAATAGTCGGAACTGC AT T C T T T AT C C C AC AAC C C T C AC AGGGT T T GC T T T AT GAAAGAGGAT GT AAT C C T C C C C T GGC T GC AAC A CTCCATTCCAGGCTCACTTCCATAAAATGGAAAGATAAACAGGTCTTTGTGTCAGAGATTTGGCATTAAC C AGAAAAC AT GAT C AAAT AT C C AC AGC T GC T C AGT C T C C C AGGC T GAAGAT T C T C T AC AGGC T T C C AT T A AGGCCACCAACATAGACTGGTGCCAGTTATTACCATCTTGGGAACATATTCAGAAATGTCTTTCCTTCCC TCCCTCCCTCCTTCTTTCCCATCCTTTCTTCCTTCTATTTATTTTCCAGGCAGGCCCATTTGTCTGCTTA GATTCAGTGACACAGAATGGGTCCAGGACCATGTCAAGACCACCTGCTGATGCTAGTGTTAGATGACTCC AGGAATGTGAGGTGTGCATCCATGGTTTCAGAATGTAATCCGTGTTGACGTGTACTGTTTGCATACTCTC AGACTGTTTTTTTTTTATGCAAAAGAAATGTTACTTTCTGGGGGAAAAAATTAAAAGTCTATCTTTCATC AACCTAAAACTTCTATATCCCCCAAACATAGAAGTTTACCTTTTTAACATTTTTCTCTCAACCTGTACAA AAATAAAAAAATTCTACATTA ( SEQ ID NO : 5 )
[0069] XM 054324369.1 PREDICTED: Homo sapiens DS cell adhesion molecule (DSCAM), transcript variant X2, mRNA
[0070] ATGATCATTTACATTTTACCTTTATGCTC C AAC TTGTTTTATCAGCCAAT T AAAAT T GAAC AGC GAAAAA TATCTTTAAAAGTTACATTTTCAAAGGGAAAAAAACATTTTTGCCCTCTTAAACTAACACTGATATTTGA TCTCAATGTTGGCCCTTTCTGTTCAACTGAAGCTTTACCGCCACTGTTTTCCTCTATTTCAGGATCTAGA T T T C T C AT C AC AT C C AC GGGAGC C T T GT AT AT T AAAGAT GT AC AGAAT GAAGAT GGAT T GT AT AAC T AC C GCTGCATCACGCGGCATCGATACACC GGAGAGAC GAGGC AGAGC AAC AGC GC C AGAC TTTTTGTAT C AGA CCCAGCGAACTCAGCCCCATCCATACTGGATGGGTTTGACCATCGCAAAGCCATGGCTGGGCAGCGTGTG GAGC T GC C T T GC AAAGC GCTCGGGCACCCT GAGC C AGAT TACCGCTGGCT GAAGGAC AAC AT GCCCCTGG AAC T T T C AGGGAGGT T C C AGAAGAC C GT GAC GGGGCTGCTCATT GAGAAC AT TCGCCCCTC GGAC T C AGG CAGCTATGTTTGTGAAGTGTCCAACAGATACGGAACTGCTAAGGTGATAGGCCGCCTGTACGTGAAACAG CCACTGAAAGCCACCATCAGTCCCAGGAAGGTTAAAAGCAGCGTGGGTAGCCAAGTTTCCTTGTCCTGCA GC GT GAC AGGAAC T GAGGAC C AGGAAC TCTCCTGGTACCGCAAT GGT GAAAT C C T C AAC C C T GGAAAAAA TGTGAGGATCACAGGGATCAACCACGAAAACCTTATAATGGATCACATGGTCAAAAGTGACGGGGGCGCA TACCAGTGCTTTGTGCGCAAGGACAAGCTGTCCGCTCAAGACTATGTGCAGGTGGTCCTTGAAGATGGAA CTCCCAAAATTATTTCTGCCTTTAGTGAAAAGGTGGTGAGTCCAGCAGAGCCGGTTTCCCTTATGTGCAA C GT GAAGGGAAC AC CTTTGCCCACGAT C AC GT GGAC C C T GGAC GAT GAC C C GAT T C T C AAGGGT GGC AGT CACCGCATCAGCCAGATGATCACGTCGGAGGGGAACGTGGTCAGCTACCTGAACATCTCCAGCTCCCAGG TCCGGGACGGGGGAGTCTACCGCTGCACTGCCAACAACTCGGCGGGAGTCGTCCTGTACCAGGCTCGAAT AAAC GT AAGAGGGC C T GC AAGC AT T C GAC C AAT GAAAAAC AT C AC AGC AAT AGC AGGAC GGGAC AC AT AC ATTCACTGTCGTGTGATTGGCTATCCGTATTACTCCATTAAATGGTACAAGAACTCTAACCTGCTTCCTT T C AAC C AC C GC C AAGT GGC AT T T GAGAAC AAT GGAAC T C T T AAAC T T T C AGAT GT GC AAAAGGAAGT GGA CGAGGGGGAGTACACGTGCAACGTGTTGGTTCAACCACAACTCTCCACCAGCCAGAGCGTCCACGTGACC GTGAAAGTTCCGCCTTTCATACAACCCTTTGAGTTTCCAAGATTCTCCATTGGGCAGCGGGTCTTCATCC CCTGTGTTGTGGTCTCAGGGGACTTACCCATCACGATCACCTGGCAGAAGGATGGCCGGCCAATCCCTGG GAGC C T T GGGGT GAC C AT T GAC AAT AT T GAC T T C AC GAGC T C C T T GAGGAT T T C C AAT C T C T C GC T C AT G C AC AAT GGGAAT T AC AC C T GC AT AGC C C GGAAT GAGGC C GC C GC T GT GGAGC AC C AAAGC C AGT T GAT T G TCAGAGTTCCTCCCAAGTTTGTGGTTCAGCCACGGGACCAGGACGGGATTTATGGCAAAGCAGTCATCCT CAATTGTTCTGCTGAGGGTTACCCTGTACCTACCATCGTGTGGAAATTCTCTAAAGGTGCTGGGGTTCCC CAGTTCCAGCCAATTGCCCTAAATGGCCGAATCCAAGTTCTCAGCAATGGGTCGTTGCTGATCAAGCATG TCGTGGAGGAAGACAGTGGCTACTACCTCTGCAAGGTCAGCAACGATGTGGGCGCAGACGTCAGCAAGTC C AT GT AC C T C AC GGT T AAAAT T C C T GC GAT GAT AAC AT C C T AT C C AAAT AC T AC C C T GGC C AC GC AGGGG C AGAAAAAGGAGAT GAGC TGCACGGCGCAT GGT GAGAAGC CCATTATAGTCCGCT GGGAGAAGGAGGAC C GAATCATTAACCCTGAGATGGCCCGTTATCTTGTGTCCACCAAGGAGGTGGGAGAAGAGGTGATTTCTAC TCTGCAGATTTTGCCAACTGTGAGAGAAGATTCTGGTTTCTTTTCCTGCCATGCTATTAATTCTTATGGG GAGGAC C GT GGAAT AAT T C AGC T C AC AGT GC AAGAGC C C C C AGAC C C T C C C GAAAT T GAGAT C AAAGAT G TCAAAGCACGCACAATTACGCTCAGGTGGACCATGGGGTTTGATGGAAACAGTCCCATCACAGGCTACGA T AT T GAAT GC AAAAAT AAAT C AGAC TCCTGGGATTCTGCT C AGAGAAC C AAAGAT GT T TCCCCTCAGCTG AAC T C GGC C AC C AT C AT T GAT AT C C AC C C T T C C T C C AC C T AC AGC AT C C GC AT GT AC GC C AAGAAC C GGA T T GGC AAGAGC GAGC C C AGC AAC GAGC TC AC CATC AC GGC GGAC GAGGC AGC TCCTGATGGTCCACCTCA GGAAGT T C AC C T GGAGC C T AT AT C AT C T C AGAGC AT C AGGGT C AC AT GGAAGGC T C C C AAGAAAC AT T T G CAAAATGGGATTATCCGTGGCTACCAAATAGGTTACCGAGAGTACAGCACTGGGGGTAACTTCCAATTCA ACATTATCAGTGTCGACACCAGCGGGGACAGTGAGGTTTACACCCTGGACAACCTGAATAAGTTCACTCA GTACGGCCTGGTGGTGCAGGCCTGTAACCGGGCCGGCACGGGGCCTTCTTCTCAGGAAATCATCACCACC AC T C T C GAGGAT GT GC C C AGT T AC C C C C C C GAAAAT GT C C AAGC C AT AGC AAC AT C AC C AGAAAGC AT AT C AAT AT C C T GGT C C AC AC T T T C C AAGGAAGC C T T GAAT GGAAT T C T C C AGGGGT T C AGAGT C AT T T AC T G GGC C AAC C T C AT GGAC GGAGAGC T GGGT GAGAT T AAAAAC AT C AC C AC C AC AC AGC C T T C AC T GGAGC T G GACGGGCTGGAAAAGTACACCAACTACAGCATCCAGGTGCTGGCCTTCACCCGCGCAGGAGACGGGGTCA GGAGTGAGCAGATCTTCACCCGGACCAAAGAGGATGTTCCAGGTCCTCCCGCGGGTGTGAAGGCAGCGGC GGCCTCAGCCTCCATGGTCTTTGTGTCCTGGCTTCCCCCTCTCAAGCTGAACGGCATCATCCGAAAGTAC ACTGTATTCTGCTCCCACCCCTATCCCACAGTGATCAGCGAGTTTGAGGCCTCTCCCGACTCGTTTTCCT ACAGAATTCCCAACCTGAGTAGGAATCGTCAGTACAGCGTCTGGGTGGTGGCTGTTACTTCAGCCGGAAG AGGC AAC AGC AGT GAAAT CAT C AC AGT C GAGC C AC T AGC AAAAGC T C C T GC AC GAAT C C T GAC C T T C AGT GGGACAGTGACTACTCCATGGATGAAAGACATTGTCTTGCCTTGTAAGGCTGTTGGGGACCCTTCTCCTG C AGT C AAAT GGAT GAAAGAC AGT AAC GGGAC AC C C AGT C T AGT AAC GATTGATGGGC GGAGGAGC AT C T T T AGC AAC GGAAGC T T C AT T AT T C GC AC GGT GAAAGC AGAAGAC T C C GGC T AT T AC AGC T GC AT T GC C AAT AACAACTGGGGATCTGATGAAATTATTTTAAACTTACAAGTACAAGTTCCACCAGATCAGCCTCGGCTTA CAGTCTCCAAGACCACGTCTTCCTCCATCACCCTTTCTTGGCTCCCTGGAGACAACGGGGGCAGCTCTAT CAGAGGATACATACTGCAGTACTCCGAGGACAATAGTGAGCAGTGGGGGAGTTTTCCAATCAGCCCCAGC GAACGTTCCTATCGCTTGGAAAATCTCAAATGTGGGACTTGGTATAAGTTCACACTGACAGCCCAAAATG GAGTGGGCCCAGGGCGCATAAGTGAAATCATAGAAGCAAAGACCTTAGGAAAAGAGCCCCAGTTCTCAAA GGAGC AGGAGC T GT T T GC C AGC AT C AAC AC C AC AC GC GT GAGGC T GAAC C T C AT T GGC T GGAAT GAT GGC GGCTGCCCCATCACCTCCTTCACACTAGAGTACAGGCCCTTTGGGACCACAGTTTGGACCACAGCTCAGA GGACCTCTCTCTCCAAGTCCTACATCCTGTATGACCTGCAGGAAGCCACCTGGTATGAGCTGCAGATGCG GGTGTGCAACAGTGCGGGCTGCGCGGAGAAGCAGGCCAACTTCGCTACGCTGAACTACGATGGCAGTACA ATTCCTCCACTCAT T AAGT C AGT T GT C C AAAAC GAAGAAGGGC T GAC GAC C AAC GAGGGGC T C AAGAT GC TGGTGACCATCTCCTGTATCCTGGTGGGGGTCTTGCTGCTGTTTGTGCTCCTGCTGGTTGTGCGGAGGAG GC GGC GGGAGC AGAGGC T AAAGAGGC TGC GAGAT GC AAAGAGT T T AGC T GAAAT GC T C AT GAGT AAGAAT AC C C GGAC T T C AGAT AC GT T AAGC AAGC AAC AGC AGAC C C T GC GAAT GC AC AT C GAC AT AC CCAGGGCTC AGCTTTTGATT GAAGAGAGAGAC AC GAT GGAGAC CATTGATGATCGCTCCACGGTTCTGTT GAC GGAT GC TGACTTTGGAGAGGCAGCTAAGCAGAAGTCCCTGACGGTCACTCACACGGTCCATTACCAATCGGTGTCT C AGGC C AC T GGGC C C T T AGT GGAT GT T T C AGAC GC T C GGC C GGGAAC GAAT C C C AC C AC C AGGAGGAAT G C C AAGGC T GGGC C C AC AGC GAGAAAC C GC T AT GC C AGC C AGT GGAC C C T C AAC C GAC C C C AC C C C AC C AT C T C AGC AC AC AC C C T C AC C AC AGAC T GGAGGC TGC C AAC AC CCAGGGCTGCAGGAT C AGT AGAC AAAGAG AGC GAC AGT T AC AGC GT C AGC C C C T C GC AAGAC AC AGAT C GAGC AAGAAGC AGC AT GGT C T C C AC AGAAA GTGCCTCCTCCACTTAC GAAGAAC TGGCCAGGGCCTAC GAAC AC GC C AAGAT GGAAGAGC AAC T GAGGC A CGCCAAGTTCACCATCACGGAGTGCTTCATATCAGACACGTCATCGGAGCAGTTGACGGCAGGGACAAAT GAGTACACGGACAGTCTGACCTCCAGCACCCCTTCCGAATCGGGAATCTGCAGGTTCACTGCATCTCCCC C C AAAC C T C AGGAT GGAGGAAGAGT AAT GAAT AT GGC AGT T C C AAAGGC AC AT C GGC C AGGT GAC C T C AT ACATTTGCCTCCATACCTTAGAATGGACTTTTTGTTAAACCGAGGTGGTCCAGGCACCAGCAGGGACCTG AGC T T AGGAC AAGC AT GC T T GGAAC C T C AGAAAAGC C GGAC C C T GAAGC GCCCCACGGTCCT GGAGC CCA TCCCGATGGAAGCCGCCTCCTCCGCCTCCTCCACGAGAGAAGGACAGTCGTGGCAGCCGGGGGCCGTGGC C AC AT T AC C T C AGC GGGAGGGAGC AGAGC T GGGAC AGGC AGC T AAAAT GAGC AGC T C C C AAGAAT C AC T G C T C GAC TCCCGGGGCCATTT GAAAGGAAAC AAT C C T T AC GC AAAAT C T T AC AC C C T GGT AT AAC AGAC AG CATGACTGGACAGCGGTTGTAAATACAATTCAAACAATTCAATCAAAGCTACCTTTTTTTTACGGAATTC CAATATTTATAAT T AAAGAAAAT TGC C AAAAT AT AT T AAAAAAAAAAAAAAGAGAAAAT AC T GAAAC C AC AGACAGTGCAAAGACTCTCCTGCTTTTTTTCTGTCTGAGTGTGAGCTCCATCCGCCTGGGCATCTGATTT TTTGGGAAAGAAGTCCAGTTTTATGATCTTCACAGGCTATTGCATTTTTACTGATTTTCTACAAAAGTGC ATGGGGGGATTAAT T AAAC C T T C T GAC T GGAAGT T C T AT C AC AC AAGAGGC AAGAAAGAAAAC AGGGT GG GTGGGAAATCAGCCTATTTGTGAATTTAAAAGGAACACCGATTTGCGGGCAGGGGAAAACTTCAGTCACG TTTGCACACCTTTCTTTCCCATTAGAAACCGGGTTCTCAATTTGGTCTTCTTTTGTTGTTAATTAGGATG AGTGCCGTCAGTGAAGGGGTGGGGGGAATCAATTTGGTTTTCTCTCTTGTTTCTTTTTTAATTTAATGAG ACACTCTTTGCATTTTGTCTAAGCGAAATAAAAAAGAAAAGGTTGTCTGCCTTTATTTCCATGTCTGCTT CTCTCGTCTTCTGCCAGTGGCCTGGTCCTCCTTCCCATTGACACTTCTGTTTGGAAACACCAGGCCTGAA C C C AGAGC C C AAT T C AAT AAAC C AGAGT C GAT AC T AAC AC C C T GAAC T C C T C AGGAAT C T C C AGGAAGC A CAAAGAAGGTGCAGCTCCTGCTCTCAAGCTGGAGAGGACAAAATGCAGGCTGGTCTCCACCGCAACCAGA GGCCAGCCCAAGTATTCGAAGCCCGTCGCAAAGCTCTGCCCCTTGCCTGCCCATGGCCAGAGTTCAACTG ACTGTGGCCTATGGGCCAAATCCAGCCTCCTGCTGTTTTTTAAATAAAGTTTTATTGAAACAAGGCCACA TGCACTATTTGCTATTGTCTATGGCTGCTTTCATGGCACAATGGTAGAGCTGAATAGTTGCAGCAGAGAT GGT AT AGC C C AT GAAGC C T AAAAT AT T T AT T AC C T GGC C C AT T AC AGGAAAC AT T T GC C AGAC C C T T GC T CTGGAGTCTGAAATGTAGCCCCAGCTTGCGTGACAAGGGGCAAGATCGTGCGTCTTACCCTCCATGACTT TTCCTATCTCCACTATGCCTGGTATGCAAATTTGTGATAGACCATCTTAATAAACATTGCCTGAATCCTC TGTAACCAGAGGAAAGTGATGTTCCTCTAAAATCTAAGTTTTTACTTTCCTTTCCCTCACTTTATCTCCC AT GT GGC T C AT C C T AAGAGAGAAT T T AC T C AT AAAT AGT C GGAAC T GC AT T C T T T AT C C C AC AAC C C T C A CAGGGTTTGCTTTTGAAAGAGGATGTAATCCTCCCCTGGCTGCAACACTCCATTCCAGGCTCACTTCCAT AAAAT GGAAAGAT AAC C AGGT C T T T GT GT C AGAGAT T T GGC AT T AAC C AGAAAAC AT GAT C AAAT AT CCA CAGCTGCTCAGTCTCCCAGGCTGAAGATTCTCTACAGGCTTCCATTAAGGCCACCAACATAGACTGGTGC CAGTTATTACCATCTTGGGAACATATTCAGAAATGTCTTTCCTTCCCTCCCTCCCTCCTTCTTTCCCATC CTTTCTTCCTTCTATTTATTTTCCAGGCAGGCCCATTTGTCTGCTTAGATTCAGTGACACAGAATGGGTC CAGGACCATGTCAAGACCACCTGCTGATGCTAGTGTTAGATGACTCCAGGAATGTGAGGTGTGCATCCAT GGTTTCAGAATGTAATCCGTGTTGACGTGTACTGTTTGCATACTCTCAGACTGTTTTTTTTTTATGCAAA AGAAATGTTACTTTCTGGGGGAAAAAATTAAAAGTCTATCTTTCATCAACCTAAAACTTCTATATCCCCC AAACATAGAAGTTTACCTTTTTAACATTTTTCTCTCAACCTGTACAAAAATAAAAAAATTCTACATTA ( SEQ ID NO : 6 )
[0071] The invention is based, in part, on the discovery by the present inventors that the inhibition of DSCAM in donor cells improves donor cell integration. The disclosure provides compositions and methods for inhibiting DSCAM, which are useful in treating a subject in need of cell replacement therapy (e.g., a subject having degeneration of the optic nerve (e.g., glaucoma)).
[0072] Inhibitory Nucleic Acids
[0073] In one aspect, the disclosure provides inhibitory nucleic acids that inhibit expression or activity of DSCAM. The inhibitory nucleic acid is a nucleic acid that specifically binds (e.g., hybridizes to) at least a portion of the DSCAM nucleic acid, such as a DSCAM RNA, pre-mRNA, or mRNA, and inhibits its expression or activity. In some embodiments, the inhibitory nucleic acid is complementary to a protein coding region or non-coding region (e.g., 5’UTR, 3’UTR, or intron) of DSCAM. In some embodiments, the inhibitory nucleic acid is complementary to a wild type DSCAM nucleic acid or a naturally occurring variant thereof. In some embodiments, the inhibitory nucleic acid is single stranded or double-stranded. In some embodiments, the inhibitory nucleic acid is a short hairpin RNA (shRNA), an anti-sense oligonucleotide (ASO), a small interfering RNA (siRNA), a double-stranded RNA (dsRNA), or a microRNA (miRNA). The inhibitory nucleic acid molecules described herein may additionally be encoded by a vector (e.g., a viral vector (e.g., a lentivirus)).
[0074] Inhibitory nucleic acid molecules may be an shRNA molecule. An shRNA molecule is a singlestranded or double-stranded nucleic acid molecule made of DNA, RNA, or both DNA and RNA (e.g., an RNA / DNA hybrid or chimeric molecule) nucleosides that are complementary to an mRNA transcript (e.g., a DSCAM transcript as described above) encoding a target, or a portion or variant thereof, and prevents translation of the mRNA into a protein or promotes the degradation of the complementary mRNA. Once a shRNA molecule enters a cell, it is incorporated into an RNA-induced silencing complex (RISC), which, upon shRNA hybridization to a target mRNA (e.g., a DSCAM transcript), the RISC complex will cleave the target mRNA, thereby inactivating the target mRNA and resulting in reduced mRNA and protein levels of the target.
[0075] The inhibitory nucleic acid molecule may be an siRNA molecule. An siRNA molecule is a singlestranded or double-stranded nucleic acid molecule made of DNA, RNA, or both DNA and RNA (e.g., a chimeric) nucleosides that are complementary to an mRNA transcript and prevents translation of the mRNA into a protein. Once an siRNA molecule enters a cell, it is incorporated into a RISC. Upon hybridization of an antisense strand of the siRNA molecule to a target mRNA (e.g., a DSCAM transcript), the RISC complex will cleave the target mRNA, thereby inactivating the target mRNA, resulting in reduced mRNA and protein levels of the target.
[0076] Inhibitory nucleic acid molecules may be a dsRNA molecule. A dsRNA molecule is a doublestranded nucleic acid molecule made of DNA, RNA, or both DNA and RNA (e.g., an RNA / DNA hybrid or chimeric molecule) nucleosides that are complementary to an mRNA transcript (e.g., a DSCAM transcript) encoding a target, or a portion or variant thereof, and prevents translation of the mRNA into a protein or promotes the degradation of the complementary mRNA. Typically, a dsRNA molecule is longer than an siRNA molecule and are processed within a cell to form an siRNA molecule. The antisense strand of the siRNA molecule is then incorporated into RISC, which, upon siRNA hybridization to a target mRNA (e.g., a DSCAM transcript), will cleave the target mRNA, thereby inactivating the target mRNA and resulting in reduced mRNA and protein levels of the target.
[0077] Inhibitory nucleic acid molecule may be a miRNA molecule. A miRNA molecule is a short, singlestranded nucleic acid molecule made of DNA, RNA, or both DNA and RNA (e.g., an RNA / DNA hybrid or chimeric molecule) nucleosides that are complementary to an mRNA transcript (e.g., a DSCAM transcript) encoding a target, or a portion or a variant thereof, and prevents translation of the mRNA into a protein or promotes the degradation of the complementary mRNA. Once a miRNA molecule enters a cell, it is incorporated into RISC, which, upon miRNA hybridization to a target mRNA (e.g., a DSCAM transcript), will cleave the target mRNA, thereby inactivating the target mRNA and resulting in reduced mRNA and protein levels of the target.
[0078] Inhibitory nucleic acid molecules may be an antisense oligonucleotide (ASO) molecule. An ASO is a single-stranded nucleic acid molecule containing DNA nucleosides that are complementary to an mRNA transcript (e.g., a DSCAM transcript) encoding a target, or a portion or variant thereof, and prevents translation of the mRNA into a protein. Upon hybridization of the ASO to a target mRNA (e.g., a DSCAM transcript), Rnase H will degrade the mRNA by hydrolyzation, resulting in reduced mRNA and protein levels of the target.
[0079] As described herein, a mammalian cell (e.g., a retinal cell (e.g., a RGC) or a neuron (e.g., dopaminergic neuron, neuronal precursor, or motor neuron)) may include an inhibitory nucleic acid molecule, so as to suppress the expression of DSCAM in the mammalian cell.
[0080] Exemplary inhibitory nucleic acid molecules that may be used in conjunction with the compositions and methods described herein are shRNA molecules, ASO molecules, siRNA molecules, dsRNA molecules, or miRNA molecules.
[0081] In some embodiments, the inhibitory nucleic acid molecule binds to a target nucleic acid sequence having at least 85% sequence identity (e.g., at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity) to a sequence provided in Table 1 (e.g., any one of SEQ ID NOs: 7 and 8).
[0082] Table 1. Exemplary target sequences. RNA sequences are shown as corresponding DNA (containing T in place of U).
[0083] In some embodiments, the inhibitory nucleic acid molecule is a shRNA. The shRNA may include a sequence complementary to at least 10 contiguous nucleotides (e.g., at least 11 , at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21 , or at least 22 contiguous nucleotides) of a nucleic acid sequence encoding DSCAM. An shRNA molecule may have at least 85% sequence identity (e.g., at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity) to a sequence in Table 2, below.
[0084] Table 2. Exemplary DSCAM-directed shRNAs. RNA sequences are shown as corresponding DNA (containing T in place of U).
[0085] In some embodiments, expression of the inhibitory nucleic acid is driven by an inducible promoter. The inducible promoter may be a doxycycline-inducible promoter, which is a nucleotide sequence that initiates transcription of a gene in the presence of doxycycline.
[0086] DSCAM inhibitors
[0087] Also provided herein are DSCAM inhibitors, which reduce the activity of DSCAM by binding to and inhibiting DSCAM. The DSCAM inhibitor may be an anti-DSCAM antibody or antigen-binding fragment thereof, a small molecule, or a polypeptide. Exemplary DSCAM antibodies or antigen-binding fragments thereof for use in the methods described herein include AF3666 (R&D Systems) or NB1 GO- 41390 (Novus).
[0088] Neurotropic factors and chemokines
[0089] Provided herein are neurotropic factors and chemokines. Administration of the neurotropic factor or chemokine has been found to improve donor cell survival and integration, for example, by altering the host microenvironment and directing donor cell migration within a tissue such as the retina.
[0090] In some embodiments, the neurotropic factor or chemokine may be stromal cell-derived factor-1 (SDF-1 ). SDF-1 and its receptor, CXCR4, are involved in various physiological and pathological processes, including the development, regeneration, and repair of the nervous system. Transplantation of stem cell-derived RGCs subretinally in combination with intravitreal delivery of recombinant SDF-1 protein to establish a chemokine gradient across the retina enhances the structural integration of the RGCs via multipolar migration. Furthermore, intravitreal delivery of SDF-1 increases the displacement of newborn RGCs out of the inner nuclear layer and toward their natural connecting points in the retina.
[0091] Mammalian cells
[0092] The disclosure further provides mammalian cells (e.g., human cells (e.g., a retinal cell (e.g., a RGC) or a neuron (e.g., dopaminergic neuron, neuronal precursor, or motor neuron))). In some embodiments, the human cell may be a RGC. RGCs are neurons in the retina that are irreversibly lost in glaucoma and other optic neuropathies. In some embodiments, the RGC may be a human stem-cell derived RGC. In some embodiments, the human cell may be a neuron (e.g., dopaminergic neuron, neuronal precursor, or motor neuron).
[0093] In some embodiments, the mammalian cell includes an inhibitory nucleic acid molecule disclosed herein. Methods for delivering nucleic acids to mammalian cells are known in the art. For example, the inhibitory nucleic acid molecule may be delivered to the mammalian cell using any suitable delivery vehicle, e.g., a vector, plasmid, or nanoparticle (e.g., a micelle, a liposome, an exosome, or a lipid nano particle (LNP)).
[0094] In some embodiments, the disclosure provides a vector (e.g., a viral vector, a mammalian vector, or a bacterial vector) for delivering the inhibitory nucleic acid to a mammalian cell. Any suitable viral vector system can be used including, e.g., a lentivirus, AAV, an adenovirus, a retrovirus, a poxvirus, a baculovirus, a herpes simplex virus, a vaccinia virus, and a synthetic virus. In some embodiments, expression of the inhibitory nucleic acid may be driven by an inducible promoter.
[0095] An exemplary vector including an inhibitory nucleic acid is provided in Table 3, below.
[0096] Table 3. Exemplary vectors.
[0097] The inhibitory nucleic acid molecule may be delivered to a mammalian cell via liposomes. Liposomes are artificially prepared vesicles which may primarily be composed of a lipid bilayer and may be used as a delivery vehicle for inhibitory nucleic acids. Liposomes can be of different sizes such as, but not limited to, a multilamellar vesicle (MLV) which may be hundreds of nanometers in diameter and may contain a series of concentric bilayers separated by narrow aqueous compartments, a small unicellular vesicle (SUV) which may be smaller than 50 nm in diameter, and a large unilamellar vesicle (LUV) which may be between 50 and 500 nm in diameter. Liposome design may include, but is not limited to, opsonins or ligands in order to improve the attachment of liposomes to unhealthy tissue or to activate events such as, but not limited to, endocytosis. Liposomes may contain a low or a high pH in order to improve the delivery of the inhibitory nucleic acid molecule.
[0098] The inhibitory nucleic acid molecule may be delivered to a mammalian cell via exosomes. Exosomes produced from cells can be collected from cell culture medium by any suitable method. Typically, a preparation of exosomes can be prepared from cell culture or tissue supernatant by centrifugation, filtration or combinations of these methods. For example, using standard methods, exosomes can be prepared by differential centrifugation, that is low speed (<20000 g) centrifugation to pellet larger particles followed by high speed (>100000 g) centrifugation to pellet exosomes, size filtration with appropriate filters (for example, 0.22 micrometer filter), gradient ultracentrifugation (for example, with sucrose gradient) or a combination of these methods.
[0099] The inhibitory nucleic acid molecules may be delivered to a mammalian cell via LNPs. For example, the inhibitory nucleic acid molecules may be formulated in a lipid nanoparticle. Exemplary commercial reagents useful for lipid-based delivery of inhibitory nucleic acid molecules including, but not limited to, TransIT-TKO™ (Mirus, Catalog No. MIR 2150), Transmessenger™ (Qiagen, Catalog No. 301525), Oligofectamine™ and Lipofectamine™ (Invitrogen, Catalog No. MIR 12252-01 1 and Catalog No. 13778-075), siPORT™ (Ambion, Catalog No. 1631 ), and DharmaFECT™ (Fisher Scientific, Catalog No. T-2001 -01 ). Compositions
[0100] The disclosure further provides compositions including a mammalian cell disclosed herein.
[0101] In some embodiments, the composition includes a mammalian cell described herein (e.g., a human cell (e.g., a retinal cell (e.g., a RGC) or a neuron (e.g., dopaminergic neuron, neuronal precursor, or motor neuron))) including an inhibitory nucleic acid described herein (e.g., SEQ ID NO: 9 or 10). In some embodiments, the composition includes a mammalian cell described herein (e.g., a human cell (e.g., a retinal cell (e.g., a RGC) or a neuron (e.g., dopaminergic neuron, neuronal precursor, or motor neuron))) including a vector described herein (e.g., SEQ ID NO: 11 ). In some embodiments, the composition further includes doxycycline. In some embodiments, the composition further includes BDNF. In some embodiments, the composition further includes GDNF. In some embodiments, the composition further includes BDNF and GDNF. In some embodiments, the composition further includes a neurotropic factor or chemokine (e.g., SDF-1 ).
[0102] In some embodiments, the composition includes a mammalian cell described herein (e.g., a human cell (e.g., a retinal cell (e.g., a RGC) or a neuron (e.g., dopaminergic neuron, neuronal precursor, or motor neuron))) and a DSCAM inhibitor (e.g., an anti-DSCAM antibody or antigen-binding fragment thereof, a small molecule, or a polypeptide). In some embodiments, the composition further includes brain-derived neurotrophic factor (BDNF). In some embodiments, the composition further includes glial cell line-derived neurotrophic factor (GDNF). In some embodiments, the composition further includes BDNF and GDNF. In some embodiments, the composition further includes a neurotropic factor or chemokine (e.g., SDF-1 ).
[0103] Those skilled in the art can determine an appropriate number of cells to include in the composition.
[0104] Methods of Treatment
[0105] The present disclosure provides methods for treating a subject, including administering an effective amount of a composition of the present disclosure.
[0106] In some embodiments, the subject has degeneration of the optic nerve, such as glaucoma. Glaucoma is a disease that affects retinal ganglion cells (RGCs), and changes at the optic nerve head where the RGC axons exit the retina are one of the first visual hallmarks of disease. The mammalian retina has a limited capacity to regenerate; thus, retinal neuron death leads to irreversible vision loss. Retinal ganglion cell (RGC) replacement is needed to recover sight loss to glaucoma. However, most donor RGCs fail to integrate into the ganglion cell layer. In some embodiments, the invention provides mammalian donor cells that integrate into the GCL by inhibiting expression or activity of DSCAM. In some embodiments, a composition of the present disclosure may be administered to the subject intravitreally or subretinally.
[0107] In some embodiments, the methods include administration of the composition as a monotherapy or in combination with one or more additional therapies. Combination therapy may mean administration of the compositions of the present disclosure to the subject concurrently, prior to, subsequent to one or more additional therapies. Concurrent administration of combination therapy may mean that the compositions of the present disclosure and additional therapy are formulated for administration in the same dosage form or administered in separate dosage forms.
[0108] In some embodiments, the one or additional therapies that may be used in combination with the inhibitory nucleic acids of the present disclosure include neurotropic factors or chemokines (e.g., SDF-1 ). In some embodiments, the neurotropic factor or chemokine (e.g., SDF-1 ) is administered to the subject (a) after administration of the composition; (b) before administration of the composition; or (c) simultaneously with administration of the composition. The neurotropic factor or chemokine may be administered to the subject intravitreally or subretinally.
[0109] In some embodiments, a subject treated in any of the methods described herein is a mammal (e.g., a human).
[0110] The actual dosage amount of a composition of the present disclosure administered to a subject can be determined by physical and physiological factors such as body weight, severity of condition, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration. Depending upon the dosage (e.g., mg / kg) and the route of administration, the number of administrations of a preferred dosage and / or an effective amount may vary according to the response of the subject. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject. Administration may occur any suitable number of times per day, and for as long as necessary.
[0111] Those skilled in the art can determine an appropriate number of cells to administer to the subject in order to treat the disorder.
[0112] EXAMPLES
[0113] The following examples are put forth so as to provide those of ordinary skill in the art with a description of how the compositions and methods described herein may be used and evaluated and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention.
[0114] Example 1. Lentivirus production of DSCAM knockout retinal ganglion cells
[0115] Cell replacement therapies have been proposed to restore lost neurons in glaucoma, Parkinson’s disease, and other neurodegenerative diseases. Donor retinal ganglion cell (RGC) survival and integration within the retina can be improved by altering the host microenvironment with neurotropic factors and chemokines. However, despite these improvements, most donor RGCs fail to integrate into the ganglion cell layer (GCL). The inventors studied the donor RGC transcriptome following transplantation and found a 6-fold lower Down Syndrome Cell Adhesion Molecule (DSCAM) expression in integrated donor RGC. The inventors identified DSCAM as a molecular feature limiting donor RGC integration into the existing circuitry. DSCAM mediates neuronal self-avoidance to preserve mosaic spacing in the retina during development, which may prevent donor RGCs from migrating toward their natural connecting points within the retina.
[0116] To knock out this vestigial homophilic molecular cue in donor RGCs, a Dox-inducible DSCAM shRNA human embryonic stem cell line (TetON-DSCAM-shRNA-hESC) was established using lentivirus particles (VectorBuilder, VB210510- 1115msb (SEQ ID NO: 11 ) with shRNA target sequences: TCCTGTACCAGGCTCGAATAAA (SEQ ID NO: 7), CCCAATGGCACTCTCCAAATTT (SEQ ID NO: 8)). RGCs were differentiated using a 3D-retinal organoid approach, and doxycycline was used to induce DSCAM knockout ~24 hours before cell dissociation, sorting, and transplantation. Results are shown in Fig. 1.
[0117] Alternatively, DSCAM may be inhibited in donor RGCs through the use of blocking antibodies or peptides.
[0118] Example 2. DSCAM knockout (KO) improves donor RGC integration into the GCL in mice
[0119] For transplantation, 2x104donor RGCs were formulated with slow-release BDNF and GDNF and injected subretinally in mice. Retinas were stained three days after transplantation and evaluated by tracking the position of donor RGCs in 3D reconstructions of retinal flat mounts (5-9 mice / group).
[0120] Results are shown in Fig. 2. DSCAM knockout in donor RGCs resulted in the spontaneous migration of 92% of donor RGCs out of the subretinal space, compared to 52% with wild-type RGCs.
[0121] These results show that DSCAM is a major inhibitor of donor neuron (RGC) migration within the retina, and that this can be overridden with a temporary DSCAM KO in donor cells, enabling translatable therapeutic approaches to neuron replacement within the central nervous system.
[0122] Example 3. Combining DSCAM KO (genetic) with chemokines improves donor RGC integration
[0123] For transplantation, donor RGCs were formulated with slow-release BDNF and GDNF and injected subretinally in mice. SDF-1 (10 ng) was injected intravitreally imminently following transplantation to study the combinatorial effect of controlling the microenvironment and intrinsic cell state. Retinas were stained three days after transplantation and evaluated by tracking the position of donor RGCs in 3D reconstructions of retinal flat mounts (5-9 mice / group).
[0124] Results are shown in Fig. 3. DSCAM knockout in donor RGCs resulted in the spontaneous migration of 92% of donor RGCs out of the subretinal space, compared to 52% with wild-type RGCs. SDF-1 treatment resulted in 69% of wild-type donor RGCs out of the subretinal space. Together, DSCAM knockout and SDF-1 treatment resulted in 86% of donor RGCs migrating out of the subretinal space, with 57% of donor RGCs migrating into the GCL compared to DSCAM knockout alone with 37% of donor RGCs migrating into the GCL.
[0125] Thus, by controlling either the tissue microenvironment or intrinsic cell state, donor RGC integration can be improved. SDF-1 significantly improves the structural integration of donor RGCs, and DSCAM is a major inhibitor of donor RGC migration within the retina. This can be overridden with a temporary DSCAM KO in donor cells, enabling translatable therapeutic approaches to neuron replacement within the central nervous system.
[0126] Example 4. Delivery of anti-DSCAM antibodies
[0127] Anti-DSCAM antibodies showed a similar effect as DSCAM KO on improving donor RGC transplantation outcome, resulting in enhanced donor RGC grafting. Results are shown in Fig. 4. For the delivery, the anti-DSCAM antibody (0.1 ug / ml) was added to the RGC suspension prior to transplantation.
[0128] Example 5. Intravitreal delivery of anti-DSCAM antibodies
[0129] Anti-DSCAM antibodies enable donor RGCs to integrate into the GCL following intravitreal delivery. Results are shown in Fig. 5.
[0130] OTHER EMBODIMENTS
[0131] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.
[0132] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the invention that come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the claims.
[0133] Some embodiments of the technology described herein can be defined according to any of the following numbered embodiments:
[0134] E1 . A mammalian cell comprising an inhibitory nucleic acid molecule capable of inhibiting expression of Down Syndrome Cell Adhesion Molecule (DSCAM).
[0135] E2. The mammalian cell of E1 , wherein the inhibitory nucleic acid molecule is a short hairpin RNA (shRNA), an anti-sense oligonucleotide (ASO), a small interfering RNA (siRNA), a doublestranded RNA (dsRNA), or a microRNA (miRNA).
[0136] E3. The mammalian cell of E1 or E2, wherein the inhibitory nucleic acid molecule is a shRNA.
[0137] E4. The mammalian cell of E3, wherein the shRNA comprises a sequence complementary to at least 10 contiguous nucleotides of a nucleic acid sequence encoding DSCAM.
[0138] E5. The mammalian cell of E3 or E4, wherein the shRNA comprises a sequence of
[0139] ACCAATGGCACTCTCCAAATTTTAGTGAAGCCACAGATGTAAAATTTGGAGAGTGCCATT GGG (SEQ ID NO: 9).
[0140] E6. The mammalian cell of E3 or E4, wherein the shRNA comprises a sequence of
[0141] CCCTGTACCAGGCTCGAATAAATAGTGAAGCCACAGATGTATTTATTCGAGCCTGGTACA GGA (SEQ ID NO: 10).
[0142] E7. The mammalian cell of any one of E1 -E6, wherein expression of the inhibitory nucleic acid is driven by an inducible promoter.
[0143] E8. The mammalian cell of E7, wherein the inducible promoter is a doxycycline-inducible promoter.
[0144] E9. The mammalian cell of any one of E1 -E8, wherein the mammalian cell is a human cell.
[0145] E10. The mammalian cell of E9, wherein the human cell is a retinal ganglion cell (RGC).
[0146] E11 . The mammalian cell of E9, wherein the human cell is a neuron (for example, a dopaminergic neuron, neuronal precursor, or motor neuron). E12. A composition comprising the mammalian cell of any one of E1 -E11 .
[0147] E13. The composition of E12, further comprising doxycycline.
[0148] E14. A composition comprising a mammalian cell and a DSCAM inhibitor.
[0149] E15. The composition of E14, wherein the DSCAM inhibitor is an anti-DSCAM antibody or antigenbinding fragment thereof.
[0150] E16. The composition of E14 or E15, wherein the mammalian cell is a human cell.
[0151] E17. The composition of E16, wherein the human cell is a RGC.
[0152] E18. The composition of E16, wherein the human cell is a neuron (for example, a dopaminergic neuron, neuronal precursor, or motor neuron).
[0153] E19. The composition of any one of E12-E18, further comprising brain-derived neurotrophic factor (BDNF).
[0154] E20. The composition of any one of E12-18, further comprising glial cell-derived neurotrophic factor (GDNF).
[0155] E21 . The composition of any one of E12-E18, further comprising BDNF and GDNF.
[0156] E22. The composition of any one of E12-E21 , further comprising a neurotropic factor or chemokine.
[0157] E23. The composition of E22, wherein the neurotropic factor or chemokine is SDF-1 .
[0158] E24. A method of treating a subject, the method comprising administering to the subject the composition of any one of E12-E21 .
[0159] E25. The method of E24, wherein the method further comprises administering to the subject a neurotropic factor or chemokine.
[0160] E26. The method of E25, wherein the neurotropic factor or chemokine is SDF-1 .
[0161] E27. The method of E25 or E26, wherein the neurotropic factor or chemokine is administered to the subject (a) after administration of the composition; (b) before administration of the composition; or (c) simultaneously with administration of the composition.
[0162] E28. A method of treating a subject, the method comprising administering to the subject the composition of E22 or E23.
[0163] E29. The method of any one of E24-E28, wherein the subject has degeneration of the optic nerve.
[0164] E30. The method of E29, wherein the subject has glaucoma.
[0165] E31 . The method of E29 or E30, wherein the composition is administered intravitreally or subretinally.
[0166] E32. The method of any one of E29-E31 , wherein the neurotropic factor or chemokine is administered to the subject intravitreally or subretinally.
[0167] E33. The method of any one of E24-E32, wherein the subject is a human.
[0168] Other embodiments are within the claims.
Claims
CLAIMS1 . A mammalian cell comprising an inhibitory nucleic acid molecule capable of inhibiting expression of Down Syndrome Cell Adhesion Molecule (DSCAM).
2. The mammalian cell of claim 1 , wherein the inhibitory nucleic acid molecule is a short hairpin RNA (shRNA), an anti-sense oligonucleotide (ASO), a small interfering RNA (siRNA), a double-stranded RNA (dsRNA), or a microRNA (miRNA).
3. The mammalian cell of claim 2, wherein the inhibitory nucleic acid molecule is a shRNA.
4. The mammalian cell of claim 3, wherein the shRNA comprises a sequence complementary to at least 10 contiguous nucleotides of a nucleic acid sequence encoding DSCAM.
5. The mammalian cell of claim 4, wherein the shRNA comprises a sequence of ACCAATGGCACTCTCCAAATTTTAGTGAAGCCACAGATGTAAAATTTGGAGAGTGCCATTGGG (SEQ ID NO: 9).
6. The mammalian cell of claim 4, wherein the shRNA comprises a sequence of CCCTGTACCAGGCTCGAATAAATAGTGAAGCCACAGATGTATTTATTCGAGCCTGGTACAGGA (SEQ ID NO: 10).
7. The mammalian cell of claim 1 , wherein expression of the inhibitory nucleic acid is driven by an inducible promoter.
8. The mammalian cell of claim 7, wherein the inducible promoter is a doxycycline-inducible promoter.
9. The mammalian cell of claim 1 , wherein the mammalian cell is a human cell.
10. The mammalian cell of claim 9, wherein the human cell is a retinal ganglion cell (RGC).11 . The mammalian cell of claim 9, wherein the human cell is a neuron (for example, a dopaminergic neuron, neuronal precursor, or motor neuron).
12. A composition comprising the mammalian cell of claim 1 .
13. The composition of claim 12, further comprising doxycycline.
14. The composition of claim 12, further comprising brain-derived neurotrophic factor (BDNF).
15. The composition of claim 12, further comprising glial cell-derived neurotrophic factor (GDNF).
16. The composition of claim 12, further comprising BDNF and GDNF.
17. The composition of claim 12, further comprising a neurotropic factor or chemokine.
18. The composition of claim 17, wherein the neurotropic factor or chemokine is SDF-1 .
19. A composition comprising a mammalian cell and a DSCAM inhibitor.
20. The composition of claim 19, wherein the DSCAM inhibitor is an anti-DSCAM antibody or antigenbinding fragment thereof.21 . The composition of claim 19, wherein the mammalian cell is a human cell.
22. The composition of claim 21 , wherein the human cell is a RGC.
23. The composition of claim 21 , wherein the human cell is a neuron (for example, a dopaminergic neuron, neuronal precursor, or motor neuron).
24. The composition of claim 19, further comprising BDNF.
25. The composition of claim 19, further comprising GDNF.
26. The composition of claim 19, further comprising BDNF and GDNF.
27. The composition of claim 19, further comprising a neurotropic factor or chemokine.
28. The composition of claim 27, wherein the neurotropic factor or chemokine is SDF-1 .
29. A method of treating a subject, the method comprising administering to the subject the composition of claim 12.
30. The method of claim 29, wherein the method further comprises administering to the subject a neurotropic factor or chemokine.31 . A method of treating a subject, the method comprising administering to the subject the composition of claim 19.
32. The method of claim 31 , wherein the method further comprises administering to the subject a neurotropic factor or chemokine.
33. The method of claim 30 or 32, wherein the neurotropic factor or chemokine is SDF-1 .
34. The method of claim 33, wherein the neurotropic factor or chemokine is administered to the subject (a) after administration of the composition; (b) before administration of the composition; or (c) simultaneously with administration of the composition.
35. A method of treating a subject, the method comprising administering to the subject the composition of claim 17.
36. A method of treating a subject, the method comprising administering to the subject the composition of claim 27.
37. The method of any one of claims 29, 31 , 35, or 36, wherein the subject has degeneration of the optic nerve.
38. The method of claim 37, wherein the subject has glaucoma.
39. The method of any one of claims 29, 31 , 35, or 36, wherein the composition is administered intravitreally or subretinally.
40. The method of claim 30 or 32, wherein the neurotropic factor or chemokine is administered to the subject intravitreally or subretinally.41 . The method of any one of claims 29, 31 , 35, or 36, wherein the subject is a human.
Citation Information
Patent Citations
Carrier for rapidly screening small interfering RNA and construction method thereof and application thereof
CN101633930B
Sustained release composition containing SDF-1
US20130243824A1
Treatment of neurological disorders
US20160346281A1
In situ and in vivo analysis of chromatin interactions by biotinylated dcas9 protein
US20190062736A1
Compositions and methods related to therapeutic cell systems expressing exogenous RNA
US20190161730A1
